New cerebral organoids and uses thereof

Olfactory mucosa stem cells are used to generate cerebral organoids without reprogramming, addressing limitations of existing methods by preserving cellular aging and epigenetic features, resulting in improved models for neurological disease studies.

WO2026234128A1PCT designated stage Publication Date: 2026-11-12HELIOS NEOPHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063163
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing cerebral organoid production methods using pluripotent stem cells fail to accurately replicate complex chronic neurological diseases due to simplified structure, developmental immaturity, and loss of cellular aging and epigenetic alterations, limiting their physiological relevance and scalability.

Method used

A method utilizing olfactory mucosa stem cells, particularly basal and ectomesenchymal stem cells, to generate cerebral organoids without reprogramming, preserving cellular aging and epigenetic modifications, resulting in organoids that mimic mature neural cell types and CNS identity.

Benefits of technology

The method produces cerebral organoids that retain donor-specific age-related features, enhancing physiological relevance and fidelity for modeling neurological conditions, suitable for personalized adult brain models and drug screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000067_0001
    Figure IMGF000067_0001
  • Figure IMGF000067_0002
    Figure IMGF000067_0002
  • Figure IMGF000069_0001
    Figure IMGF000069_0001
Patent Text Reader

Abstract

The present invention relates to new cerebral organoids and a method of production of cerebral organoids More particularly, the present invention relates to a method to produce cerebral organoids from olfactory mucosa stem cells obtained from the nasal mucosa of a subject. The present invention further relates to the use of such organoids in particular in the medical field.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] New cerebral organoids and uses thereof

[0002] Technical field

[0003] The present invention relates to new cerebral organoids and a method of production of cerebral organoids. More particularly, the present invention relates to a method to produce cerebral organoids from olfactory mucosa stem cells obtained from the nasal mucosa of a subject. The present invention further relates to the use of such organoids in particular in the medical field.

[0004] Background art

[0005] The olfactory system serves as a unique window into neurological disorders due to its direct connection to the brain and its vulnerability to pathological changes. Experimental evidences have suggested a concomitant role of olfactory bulb neurons in the onset of decline in olfactory acuity as well as the initiation of neurodegenerative pathology. Olfactory impairment such as anosmia is a potential early marker for the onset of neurodegenerative diseases, including Alzheimer's disease, Parkinson disease, multiple sclerosis, and schizophrenia. Furthermore, several markers of neurodegenerative diseases, such as Alzheimer’s disease, have been detected in the olfactory neuroepithelium. Indeed, characteristic proteins such as hyperphosphorylated Tau and beta-amyloid plaques, traditionally associated with neuronal degeneration in the brain, have also been identified in olfactory cells. This observation suggests that the olfactory neuroepithelium could reflect, or even precede, certain pathological changes occurring in the brain.

[0006] Cerebral organoids, three-dimensional cell cultures that recapitulate aspects of human brain development, have emerged as valuable in vitro models for studying neurodevelopmental processes, disease mechanisms, and therapeutic interventions. These organoids are typically generated using pluripotent stem cells, such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), which are directed to differentiate into neural lineages under specific culture conditions. Cerebral organoids are composed of neurons and glial cells derived from ESCs or iPSCs. The iPSCs are generated through a reprogramming process that transforms any somatic cell into a pluripotent stem cell capable of differentiating into all cell types in the body. One of the main advantages of cerebral organoid models is their ability to retain the species and patient-specific genetic background. These models encompass genes that predispose individuals to neurological diseases while providing a 3D complex cytoarchitecture, as opposed to existing in vitro models. Growing numbers of organoid protocols have been developed to recapitulate distinct brain regions, subregions, and combine multiple brain region.The applications of organoids are extensive and can be implemented in fundamental research, drug discovery, diagnostics, stratification of clinical trials, and in fine, precision medicine.

[0007] However, while cerebral organoids have proven effective in modeling brain development and neurodevelopmental disorders, they still have limitations when it comes to accurately reproducing complex chronic neurological diseases. They feature a simplified structure lacking the full cellular diversity. Cerebral organoids often exhibit developmental immaturity, struggling to fully replicate the complexity and timeline of human brain development. Moreover, the reprogramming of somatic cells not only erases the cellular aging state but also eliminates underlying epigenetic alterations associated with neurological disorders.

[0008] Recently, organoids have been developed, from olfactory mucosa stem cells. However, the resulting organoids corresponded to olfactory organoids, that retained their olfactory identity and did not mimic cerebral organoids. Indeed, they contained olfactory sensory neurons of the peripheral nervous system rather than neurons of the central nervous system.

[0009] Thus, there remains a need for improved methods for generating cerebral organoids that overcome the limitations associated with prior approaches. The present invention addresses at least partially these issues by providing a novel approach for cerebral organoid production that enhances reliability, scalability, and physiological relevance.

[0010] Summary of the invention

[0011] By working on these issues, the inventors have discovered that stem cells of the peripheral nervous system, in particular basal stem cells and mesenchymal stem cells, may be used to produce cerebral organoids without a reprogramming step. In particular, the inventors have shown that olfactory mucosa stem cells of a subject may be used to produce cerebral organoids without a reprogramming step. More specifically, they have demonstrated that basal and / or ectomesenchymal stem cells from the olfactory mucosa can give rise to cerebral organoids under defined culture conditions. This direct conversion process avoids the need for pluripotent reprogramming and provides significant advantages over conventional organoid generation methods. Notably, it preserves the original epigenetic modifications and retains the cellular aging features of the donor cells, thereby improving the physiological relevance and fidelity of the resulting organoids for modeling age-related or epigenetically driven neurological conditions.

[0012] It is therefore an object of the present invention to provide a method of producing a cerebral organoid from olfactory mucosa stem cells, comprising culturing and differentiating olfactorymucosa stem cells into neurons and glial cells. Advantageously, the method is implemented without a reprogramming step, i.e., the method of producing a cerebral organoid is deprived of a reprogramming step. The absence of reprogramming step allows to maintain the cellular aging and key epigenetic modifications of the olfactory mucosa stem cells used to produce the organoid.

[0013] Advantageously, the method of the invention produces a cerebral organoid from olfactory mucosa stem cells, only. That is to say that the olfactory mucosa stem cells are the sole source of cells used to generate the cerebral organoid.

[0014] Preferably, the olfactory mucosa stem cells are selected from olfactory basal stem cells, olfactory ectomesenchymal stem cells (OE-MSCs) or a combination thereof.

[0015] The olfactory mucosa stem cells may be obtained from any mammal, in particular from a human mammal. For instance, the olfactory stem cells may be obtained from a subject, in particular a human, exhibiting a neurological disorder, preferably selected from a neurodegenerative disorder or a neuropsychiatric disorder, more preferably selected from Alzheimer's disease, Parkinson's disease, schizophrenia, or bipolar disorder.

[0016] In an embodiment, the cultivation step leads to formation of cellular spheres and the differentiation step may be performed before or after aggregation of the cellular spheres into organoids.

[0017] In an embodiment, the method comprises the steps of (i) culturing the olfactory mucosa stem cells to obtain cellular spheres; (ii) aggregating said cellular spheres to form organoids; (iii) culturing successively said organoids in adapted culture medium to differentiate cells of the organoids respectively into neurons and glial cells, in particular astrocytes and oligodendrocytes, in order to obtain cerebral organoids.

[0018] In another embodiment, the method comprises the steps of (i) culturing the olfactory mucosa stem cells to obtain cellular spheres; (ii) culturing said spheres in adapted culture medium to differentiate the cells respectively into neurons and glial cells, in order to obtain spheres of neurons and spheres of glial cells, in particular spheres of astrocytes and spheres of oligodendrocytes; (iii) aggregating spheres of neurons and spheres of glial cells to form cerebral organoids.

[0019] In another embodiment, the method comprises the steps of (i) transdifferentiating the olfactory mucosa stem cells to obtain neuronal stem cells; (ii) culturing the neuronal stem cells to obtainneurospheres; (iii) aggregating said neurospheres to form neuronal organoids; (iv) culturing said neuronal organoids to differentiate the neuronal stem cells into neurons and glial cells, in particular astrocytes and oligodendrocytes.

[0020] The method of the invention advantageously may allow to obtain organoids comprising mature neurons, preferably expressing TUJ1 (class III P-tubulin) and / or the neuronal nuclear protein (NeuN). Similarly or in addition, the method of the invention may allow to obtain organoids comprising glial cells selected from astrocytes, preferably expressing Glial Fibrillary Acidic Protein (GFAP), oligodendrocytes, preferably expressing Olig2, and / or ependymal cells, and any combination thereof.

[0021] Advantageously, the method of the invention allows to obtain cerebral organoids deprived of sensory neurons. In particular, the organoids obtained are preferably free, or substantially free of neurons expressing Olfactory Marker Proteins (OMP) and / or neurons expressing Peripherin. It is a further object of the invention to propose the use of olfactory mucosa stem cells to produce a cerebral organoid.

[0022] According to the invention, the olfactory mucosa stem cells are preferably selected from olfactory basal stem cells, olfactory ectomesenchymal stem cells or combination thereof. According to the invention, the basal and / or ectomesenchymal stem cells are the sole source of cells used to generate the cerebral organoids of the invention.

[0023] In a particular embodiment, the olfactory stem cells were previously collected from olfactory mucosa of a subject exhibiting a neurological disorder, in particular a neurodegenerative disorder. Alternatively, the olfactory stem cells may be obtained from a healthy subject.

[0024] Advantageously, the neurons in the organoids are selected from motor neurons, sensory neurons, and combination thereof. Alternatively or in addition, the glial cells are advantageously selected from astrocytes, oligodendrocytes, ependymal cells, and any combination thereof.

[0025] It is a further object of the present invention to provide a cerebral organoid obtainable by the method of the invention. More generally, it is an object of the present invention to provide cerebral organoids obtained from olfactory mucosa stem cells of a subject, in particular from basal stem cells and / or ectomesenchymal stem, that show mature neural cell types (e.g., matures neurons, glial cells). The organoids of the present invention advantageously retain subject’s epigenetic alterations and aging status.In a particular embodiment, the cerebral organoid is obtained from olfactory mucosa stem cells of a subject showing a neurological or neurological disorder. For instance, the cerebral organoid is obtained from olfactory mucosa stem cells of a subject with Alzheimer disease. Alternatively, the cerebral organoid is obtained from olfactory mucosa stem cells of a healthy subject, without neurological or neurodegenerative disorder.

[0026] It is a further object of the present invention to provide cerebral organoid obtained from olfactory mucosa stem cells, comprising mature neurons expressing TUJ1 (class III P-tubulin), the neuronal nuclear protein (NeuN) and / or the Microtubule Associated Protein-2 (MAP2) and glial cells selected from astrocytes and / or oligodendrocytes. Advantageously, since no reprogramming step is required, the cellular aging and key epigenetic modifications of the olfactory mucosa stem cells used to produce the organoid are maintained in the organoid.

[0027] In a particular embodiment, the organoid comprises mature neurons expressing TUJ1, NeuN and MAP2, astrocytes expressing GFAP and oligodendrocytes expressing Olig2.

[0028] The cerebral organoid may further comprise neural stem cells.

[0029] In a particular embodiment, the cerebral organoid is deprived of neurons expressing Olfactory Marker Proteins (OMP) and / or neurons expressing Peripherin. That is to say that the organoid does not exhibit an olfactory identity nor a peripheral nervous system identity.

[0030] The cerebral organoid may also be vascularized.

[0031] It is further object of the present invention to provide a method of producing a vascular organoid from olfactory mucosa-derived cells of a subject, comprising differentiating olfactory ectomesenchymal stem cells (OE-MSCs) under angiogenic conditions to obtain pericyte-like cells expressing one or more markers selected from NG2, PDGFR-P and a-SMA, optionally in combination with endothelial cells derived from OE-MSCs by transdifferentiating and / or isolated directly from the olfactory mucosa of the subj ect, and assembling said cells into a three-dimensional vascular organoid structure, said method being deprived of a reprogramming step.

[0032] Advantageously, the biological and epigenetic age of the olfactory mucosa stem cells used to produce the organoid are substantially retained within the cerebral organoid and / or vascular organoid, notwithstanding minor variations attributable to culture conditions and / or passaging.

[0033] The methods of the present invention are particularly suited to generate personalized adult brain models, enabling the study of age-related neurological diseases, neurodegeneration or brain aging processes in vitro. The cerebral organoids of the invention are also suited for screeningfor a prophylactic or therapeutic drug for a neurological disorder. The cerebral organoids of the invention may also be used for prevention, clinical trial stratification, diagnosis, prediction of disease progression, precision medicine, toxicity assessment, studying aging and brain function, etc.

[0034] More generally, the present invention allows the generation of three-dimensional non-olfactory neural organoids from olfactory mucosa stem cells without reprogramming to a pluripotent state. Advantageously, the organoids of the invention are multicellular organoids comprising neurons, astrocytes and oligodendroglial lineage cells with CNS-like molecular features. Preferably, the cerebral organoid of the invention exhibits divergence from olfactory sensory neuron identity as evidenced by absence or near-absence of OMP and Peripherin expression. Advantageously, the present invention allows to preserve the donor-associated age-related molecular features as a result of the absence of epigenetic reprogramming.

[0035] Legend to the drawings

[0036] Figure 1 : Generation of cerebral organoids from nasal biopsy-derived stem cells. This schematic illustrates the step-by-step process of generating cerebral organoids from a patient's nasal biopsy.

[0037] Figure 2 : Immunocytochemical characterization of basal stem cells from the mouse olfactory mucosa. (A) Immunofluorescence staining for K14 , a basal cell marker. (B) Sox2 staining, a transcription factor associated with sternness. (C) Merged image showing co-expression / colocalization of KI 4 and Sox2, with nuclear counterstaining using Hoechst. Magnifications typically 40 or x 63.

[0038] Figure 3 : Immunofluorescence characterization of organoids derived from mouse olfactory mucosa stem cells after 2 weeks of differentiation. (A) Sox2 staining identifies stem / progenitor cells within the organoid structure. (B) Tuj 1 staining reveals neuronal differentiation and the presence of neurite-like projections. (C) Merged image showing distinct compartmentalization between Sox2-positive stem / progenitor cells and Tuj 1 -positive mature neurons, with nuclear staining using Hoechst. Images acquired at 63 x magnification.

[0039] Figure 4 : Immunocytochemical characterization of human ectomesenchymal stem cells (ectoMSCs) cultured in 2D conditions. (A) Brightfield microscopy image of adherent ectoMSCs cultured in serum-containing medium on day 3 post-seeding (DIV3). The cells exhibit typical fibroblast-like morphology and strong adherence to the culture surface. (B-D) Immunofluorescence staining showing the expression of key reference markers in fixedectoMSCs: (B) Nestin staining, a neural stem cell marker, with nuclear counterstaining using Hoechst, imaged at 63 x magnification; (C) CD73 staining, a classical mesenchymal marker, with Hoechst counterstaining, 63 x magnification; (D) S100A4 staining, associated with mesenchymal cells and cell migration, with Hoechst nuclear staining, 63 x magnification.

[0040] Figure 5 : Organoid formation from ectomesenchymal stem cells (ectoMSCs) derived from healthy donors. (A) Brightfield image of adherent ectoMSCs cultured in serum-containing medium at day 3 post-seeding (DIV3), showing typical fibroblast-like morphology (20 x magnification). (B) Formation of uniform spheroids under non-adherent conditions, indicative of cellular aggregation and viability in suspension culture (40 x magnification). (C) Fusion of individual spheroids and onset of organoid morphogenesis under optimized culture conditions (40x magnification). (D) Mature organoid structure formed from ectoMSCs, displaying compact and organized morphology after 2 weeks differentiation under brightfield microscopy (20x magnification). These observations demonstrate the capacity of ectoMSCs to self-organize into 3D structures, supporting their potential for use in organoid-based modeling and regenerative applications.

[0041] Figure 6 : Organoid formation from ectomesenchymal stem cells (ectoMSCs) derived from Alzheimer’s disease patients. (A) Formation of uniform spheroids under non-adherent culture conditions, observed at 10x magnification. (B-D) Progressive fusion of spheroids and early stages of organoid morphogenesis under optimized differentiation conditions, captured at 40 x magnification. (E) Formation of a proliferative organoid structure, exhibiting compact morphology during the expansion phase (40x magnification). These images illustrate the ability of Alzheimer’s patient-derived ectoMSCs to aggregate, fuse, and self-organize into 3D organoid structures, suggesting their applicability in disease modeling and regenerative studies.

[0042] Figure 7 : Neuronal differentiation within organoids derived from healthy donor ectomesenchymal stem cells (ectoMSCs). Immunofluorescence analysis of ectoMSC-derived organoids after 2 weeks of differentiation. (A) Tujl staining (green) reveals the presence of mature neurons distributed throughout the organoid structure. (B) Merged image showing Tuj 1 (green) and Hoechst nuclear staining (blue), confirming neuronal identity and cellular organization within the organoid. Images acquired at 63 x magnification. These results demonstrate the neurogenic potential of ectoMSCs under appropriate differentiation conditions, leading to the formation of neuron-rich 3D organoids.

[0043] Figure 8: Expression of proliferation and neural markers in eMSCs-derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from eMSCs patient cells at day 56. Samples are stained for (A) Ki67 for cell proliferation (red), (B) Nestin forneural stem cells (red) and (C) Doublecortin (DCX) for immature neurons (green). Nuclei were counterstained with Hoechst (blue). Scale bar = 100 gm. The organoids display a combination of proliferative and neural progenitor-like features, as evidenced by Ki67 and Nestin expression. The presence of DCX-positive cells further indicates early neuronal commitment. These observations suggest the establishment of a dynamic cellular system undergoing progressive neural differentiation rather than a terminally differentiated culture.

[0044] Figure 9: Characterization of neuronal and glial differentiation in eMSCs -derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from eMSCs patient cells at day 56. Samples are stained for (A) NeuN for mature neurons (green), (B) GFAP for astrocytes (red) with scale bar = 100 gm. (C) Co-expression of Tuj 1 for neurons (green) and Sox2 for neural stem cells (red) with scale bar = 50 pm. Nuclei were counterstained with Hoechst (blue). The persistence of Nestin- and Sox2-positive cells at later stages indicates the maintenance of a progenitor-like compartment over time. In parallel, the presence of TUJ1-positive cells suggests ongoing differentiation, pointing to a dynamic balance between proliferation and maturation within the organoids.

[0045] Figure 10: Marker expression in mature eMSCs derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from eMSCs patient cells at day 90. Samples are stained for (A) Nestin (green) and Pax6 (red) for neural stem cells. (B) Co-expression of Tuj 1 for neurons (green) and Sox2 for neural stem cells (red). Nuclei were counterstained with Hoechst (blue). Scale bar = 50 pm. The persistence of Nestin- and Sox2-positive cells at later stages indicates the maintenance of a progenitor-like compartment over time. In parallel, the presence of TUJ1 -positive cells suggests ongoing differentiation, pointing to a dynamic balance between proliferation and maturation within the organoids.

[0046] Figure 11: Assessment of maturation in long-term cultured eMSCs derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from eMSCs patient cells at day 90. Samples are stained for (A) DCX (green) and MAP2 (red) for respectively immature and mature neurons. (B) Co-expression of NeuN for mature neurons (green) and GFAP for astrocytes (red). Nuclei were counterstained with Hoechst (blue). Scale bar = 50 gm. The detection of both immature (DCX) and mature neuronal markers (MAP2, NeuN), together with astrocytic cells (GFAP), indicates progressive maturation and diversification of neural cell types. This supports the notion of a developing neural tissue-like structure rather than a static differentiated population.

[0047] Figure 12: Assessment of olfactory markers expression in eMSCs derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from eMSCs patientcells at day 90. Samples are stained for (A) OMP for olfactory neurons (green) and (B) Peripherin for peripheral neurons (red). (C) Nuclei were counterstained with Hoechst (blue). Scale bar = 50 pm. Immunofluorescence analysis demonstrated absent expression of OMP and Peripherin in eMSC-derived organoids at day 90, confirming that these organoids have acquired central nervous system identity and do not retain olfactory sensory neuron identity. This observation indicates a divergence from the original tissue-specific phenotype.

[0048] Figure 13: Expression of proliferation and neural markers in olfactory basal cells-derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from olfactory basal cells at day 56. Samples are stained for (A) Ki67 for cell proliferation (red), scale bar= 50 pm. (B) Pax6 for neural stem cells (red), scale bar= 100 pm. Nuclei were counterstained with Hoechst (blue). Basal cell-derived organoids exhibit both proliferative activity (Ki67) and expression of neural-associated markers (Pax6), suggesting that these cells can adopt a neural progenitor-like phenotype under organoid-forming conditions.

[0049] Figure 14: Characterization of neuronal and glial differentiation in olfactory basal cells-derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from olfactory basal cells at day 56. Samples are stained for (A) NeuN for mature neurons (green) and GFAP for astrocytes (red). (B) Co-expression of Tujl for neurons (green) and Sox2 for neural stem cells (red). (C) Co-expression of DCX for immature neurons (green) and MAP2 for mature neurons (red). Nuclei were counterstained with Hoechst (blue). Scale bar = 50 pm. The simultaneous presence of neuronal and glial markers, along with progenitor-associated Sox2 expression, further supports the generation of a multicellular neural environment. The detection of both immature and mature neuronal markers suggests ongoing differentiation and maturation processes within the organoids.

[0050] Figure 15: Assessment of olfactory markers expression in olfactory basal cells derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from olfactory basal cells at day 56. Samples are stained for (A) OMP for olfactory neurons (green) and (B) Peripherin for peripheral neurons (red). (C) Nuclei were counterstained with Hoechst (blue). Scale bar = 20 pm. Organoids derived from olfactory basal stem cells did not express OMP or Peripherin at day 56, as confirmed by immunofluorescence. This finding is particularly significant given that olfactory basal stem cells are the direct in vivo progenitors of olfactory sensory neurons, and would be expected to follow an olfactory differentiation program under standard neural induction conditions. The complete absence of OMP and Peripherin expression in basal cell-derived organoids demonstrates that these cells have diverged from their tissue-of-origin olfactory differentiation program and have acquired acentral nervous system neuronal identity under the culture conditions of the present invention. This result is consistent with the absence of OMP and Peripherin observed in organoids derived from olfactory ectomesenchymal stem cells (Figure 12), demonstrating that the suppression of olfactory identity and the acquisition of CNS neuronal identity is a robust and reproducible property of the cerebral organoids of the invention, irrespective of the olfactory mucosa-derived cell population used.

[0051] Figure 16: Assessment of glial differentiation markers expression in olfactory basal cells derived organoids. Confocal immunofluorescence images of cross-sections from organoids derived from olfactory basal cells at day 56. Samples are stained for (A) GFAP for astrocytes (red) with scale bar = 50 pm. (B) Olig 2 for oligodendrocyte lineage (red) with scale bar = 100 pm. Nuclei were counterstained with Hoechst (blue). The presence of GFAP -positive astrocytes and Olig2 -positive cells indicates the emergence of distinct glial lineages within the organoids, contributing to their cellular diversity.

[0052] Figure 17: Quantification of marker-positive cells in basal cells- (BC-) and eMSC-derived organoids at day 18 (DIV 18). Bar graphs show the percentage (%) of cells positive for the indicated markers (AQP4, CD140a, CD24, GFAP, Nestin, Sox2, and Tujl) in BC-derived organoids (left) and eMSC-derived organoids (right) at DIV18. The experiment was performed in three independent biological replicates, each including three technical replicates. Bars indicate mean ± SEM. Quantitative analysis confirms the presence of multiple neural cell populations, including progenitor-like, neuronal, and glial cells. The relative distribution of these markers supports the establishment of a heterogeneous and organized cellular system within the organoids.

[0053] Description of the invention

[0054] The present invention provides methods for the in vitro generation of cerebral organoids that mimic structurally and functionally cerebral parts of a subject. The organoids of the present invention are generated from olfactory mucosa stem cells of a subject and may include both neuronal cells and glial cells. The organoids of the present invention may be used to provide improved models of the nervous system under normal and disease conditions, depending on the subject who provides the stem cells used to generate said organoid. The following is a description of the present invention, including preferred embodiments thereof given in general terms. The present invention is further exemplified in the disclosure given under the heading “Examples” herein below, which provides experimental data supporting the invention and means of performing the invention.In particular, the present invention relates to a novel method for generating three-dimensional cellular structures that recapitulate morphological, molecular, and functional characteristics of the adult human brain, using somatic stem cells derived from the olfactory mucosa, while preserving their intrinsic cellular age. Unlike conventional approaches that rely on cellular reprogramming to a pluripotent state, thereby resetting the epigenetic and biological age of the cells, the present invention allows the generation of cerebral organoids without erasing the donor cells' age-related identity, thus faithfully modeling the adult brain, rather than an embryonic or developmental stage. Key innovative features of the invention include the use of adult olfactory mucosa-derived stem cells, easily accessible and harvested without invasive procedures, no genetic reprogramming, thereby preserving the donor's biological and epigenetic age, the formation of cerebral organoids showing mature neural cell types (e.g., mature neurons, glial cells), the suitability for generating personalized adult brain models, enabling the study of age-related neurological diseases, neurodegeneration, or brain aging processes in vitro.

[0055] Definitions

[0056] The present disclosure will be best understood by reference to the following definitions.

[0057] Unlike conventional two-dimensional (2D) cell cultures, cerebral organoids grow in a three-dimensional (3D) configuration, enabling the development of more physiologically relevant tissue architecture and cellular organization. As used herein, the terms “cerebral organoid,” “3D brain tissue,” or “brain organoid” refer to self-organizing three-dimensional cellular structures that mimic key anatomical and functional features of the mammalian brain. In contrast to neurospheres, which consist of spherical clusters of neural progenitor cells cultured in suspension and generally lack spatial organization, cerebral organoids exhibit region-specific cellular differentiation, stratified structures, and, in certain cases, early forms of brain-like compartmentalization. As such, cerebral organoids constitute a more advanced and representative in vitro model for investigating brain development, function, and pathology.

[0058] As used herein, the term “subject”, “individual,” or “patient” refers to human, including adult and child, and veterinary subj ects particularly non-human mammal. In a particular embodiment, the subject is a human being that exhibits a neurological disorder, in particular a neurodegenerative disease, such as Alzheimer’s disease.

[0059] As used herein, a “neurological disorder”, “neurological disorder” or “neurological condition" refers to a medical condition that affects the structure, function, or physiology of the nervous system of a subject, which includes the brain, spinal cord, and peripheral nerves. These disorders can arise from genetic, environmental, infectious, autoimmune, traumatic, metabolic,vascular, or degenerative causes, leading to a wide range of symptoms such as cognitive decline, movement impairments, sensory dysfunction, pain, or autonomic disturbances. Neurological disorders include without limitation, neurodegenerative disease and neuropsychiatric disorder. A “neurodegenerative disease” refers to a subset of neurological disorders characterized by progressive degeneration and loss of neurons, leading to functional impairments over time. Examples of neurodegenerative disease include, without limitation Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS).

[0060] “Neuropsychiatric disorder" encompasses mental disorders attributable to diseases of the nervous system, Non-limiting examples of neuropsychiatric disorders include addictions, childhood developmental disorders, eating disorders, degenerative diseases, mood disorders, neurotic disorders, psychosis, sleep disorders, depression, obsessive-compulsive disorder, schizophrenia, visual hallucination, auditory hallucination, eating disorder, bipolar disorder, epilepsy, autism spectrum disorder (ASD).

[0061] The term "treatment" refers to any act intended to ameliorate the health status of patients such as therapy, prevention, prophylaxis and retardation of the disease or of the symptoms of the disease. It designates both a curative treatment and / or a prophylactic treatment of a disease. A curative treatment is defined as a treatment resulting in cure or a treatment alleviating, improving and / or eliminating, reducing and / or stabilizing a disease or the symptoms of a disease or the suffering that it causes directly or indirectly. A prophylactic treatment comprises both a treatment resulting in the prevention of a disease and a treatment reducing and / or delaying the progression and / or the incidence of a disease or the risk of its occurrence. In certain embodiments, this term refers to minimizing the spread or the worsening of a disorder or disease. Treatments according to the present invention do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect.

[0062] The terms "cell culture medium", "culture medium" or "medium" as used herein refer to a medium for culturing cells containing nutrients that maintain ceil viability and support proliferation. The cell culture medium may contain any of the following in an appropriate combination: salt(s), buffer(s), amino acids, glucose or other sugar(s), antibiotics, serum or serum replacement, and other components such as peptide growth factors, etc. Cell culture media ordinarily used for particular cell types are known to those skilled in the art.

[0063] As used herein, the term "stem cells" refers to a cell that retains the ability to renew itself through mitotic cell division and that can differentiate into a diverse range of specialized celltypes. Mammalian stem cells can be divided into three broad categories: embryonic stem cells, which are derived from blastocysts, adult stem cells, which are found in adult tissues, and cord blood stem cells, which are found in the umbilical cord.

[0064] As used herein, the term “adult cell” refers to a cell found throughout the body of a mammal, in particular a human mammal, after embryonic development.

[0065] The term "pluripotent" as used herein refers to a cell with the capacity to differentiate to more than one differentiated cell type, and preferably to differentiate to cell types characteristic of all three germ cell layers, Pluripotent cells are characterized primarily by their ability to differentiate to more than one cell type, preferably to all three germ layers, using, for example, a nude mouse teratoma formation assay. Pluripotency is also evidenced by the expression of embryonic stem (ES) cell markers, although the preferred test for pluripotency is the demonstration of the capacity to differentiate into cells of each of the three germ layers, It should be noted that simply culturing such cells does not, on its own, render them pluripotent, Reprogrammed pluripotent cells (e,g., iPS cells as that term is defined herein) also have the characteristic of the capacity of extended passaging without loss of growth potential, relative to primary cell parents, which generally have capacity for only a limited number of divisions in culture.

[0066] By working on the development of cerebral organoids to study neurological conditions, the inventors have discovered that certain cells of the olfactory mucosa may be efficiently used to generate cerebral organoids. It was the merit of the inventors to discover that some adult stem cells, and more particularly olfactory mucosa stem cells retain a broad multipotent differentiation potential that extends beyond their tissue-of-origin olfactory lineage, enabling their differentiation into central nervous system neuronal and glial cell types, without requiring reprogramming to a pluripotent state. More particularly, the inventors have shown that olfactory basal stem cells and / or olfactory ectomesenchymal stem cells of a subject may be used to produce a cerebral organoid.

[0067] The olfactory mucosa is a specialized region of the nasal mucosa responsible for the sense of smell. It is located in the upper part of the nasal cavity, covering the superior nasal concha and a portion of the nasal septum. This tissue is easily biopsied, under local anesthesia. The olfactory mucosa comprises the olfactory epithelium and the lamina propria. The olfactory epithelium is characterized by the presence of sustentacular and basal cells (BC). The basal cells are stem cells that regenerate olfactory receptor neuron while sustentacular cells provide structural and metabolic support to the olfactory neurons. The lamina propria is characterized by ectomesenchymal stem cells. Ectomesenchymal stem cells (eMSC or ectoMSC) are asubtype of mesenchymal stem cells (MSC) that belong to the nervous tissue and are involved in the permanent neurogenesis that takes place all lifelong in the olfactory mucosa. Importantly, both basal cells and ectomesenchymal stem cells possess multipotent differentiation potential. Basal cells have been shown to give rise not only to olfactory sensory neurons but also to supporting glial-like cells under certain conditions. Similarly, ectomesenchymal stem cells are capable of differentiating into various cell types, including neuronal, glial, and mesodermal lineages such as osteogenic, adipogenic, and chondrogenic cells. The presence of these two multipotent stem cell populations within the olfactory mucosa highlights its potential as a valuable and minimally invasive source of stem cells for generating complex neural structures, such as cerebral organoids.

[0068] Both basal stem cells (BC) and ectomesenchymal stem cells (eMSC) are adult stem cells that may be used to produce a cerebral organoid without reprogramming said cells before.

[0069] The term "reprogramming" as used herein refers to the process that alters or reverses the differentiation state of a somatic cell. Reprogramming encompasses complete reversion of the differentiation state of a somatic cell to a pluripotent cell. Such complete reversal of differentiation produces an induced pluripotent (iPS) cell. Reprogramming generally involves alteration, e.g. , reversal, of at least some of the heritable patterns of nucleic acid modification (e.g, , methylation), chromatin condensation, epigenetic changes, genomic imprinting, etc. , that occur during cellular differentiation as a zygote develops into an adult.

[0070] The present invention thus provides the use of olfactory mucosa stem cells previously collected from olfactory mucosa of a subject to produce a cerebral organoid.

[0071] Advantageously, the olfactory stem cells are selected from olfactory basal stem cells, olfactory ectomesenchymal stem cells and combination thereof.

[0072] In a particular embodiment, the olfactory mucosa stem cells used to implement the method of the invention are basal stem cells only.

[0073] In another particular embodiment, the olfactory mucosa stem cells used to implement the method of the invention are ectomesenchymal stem cells only.

[0074] In another particular embodiment, the olfactory mucosa stem cells used to implement the method of the invention are both basal stem cells and ectomesenchymal stem cells.

[0075] The present invention relates to a novel method for generating three-dimensional cellular structures that recapitulate morphological, molecular, and functional characteristics of the adulthuman brain, using somatic stem cells derived from the olfactory mucosa, while preserving their intrinsic cellular age.

[0076] Unlike conventional approaches that rely on cellular reprogramming to a pluripotent state, thereby resetting the epigenetic and biological age of the cells, the present invention allows the generation of cerebral organoids without erasing the donor cells' age-related identity, thus faithfully modeling the adult brain, rather than an embryonic or developmental stage.

[0077] In the context of the invention, the terms "preserving", "maintaining" or "retaining" the cellular aging and / or the epigenetic modifications of the donor cells mean that the olfactory mucosa stem cells have not been subjected to a reprogramming step that would reset their epigenetic clock or erase their age-related molecular signatures. As a result of the absence of such reprogramming, the biological and epigenetic age of the cells used to produce the organoid are substantially retained. It will be understood that some degree of change in age-associated parameters may occur as a result of culture conditions and passaging, such that the biological age of cells within the organoid may differ slightly from that of the original donor tissue. Such culture-induced changes do not constitute reprogramming and do not preclude the organoid from being considered as retaining the biological age of the donor subject within the meaning of the present invention.

[0078] It is the purpose of the present invention to provide a method for generating a three-dimensional neural structure with adult brain-like features, the method comprising:

[0079] culturing stem cells derived from the olfactory mucosa of a subject under conditions that promote spatial aggregation into spheroid formations;

[0080] - transitioning the spheroids into any biomimetic three-dimensional environment, such as an extracellular matrix or biocompatible hydrogel, that supports cellular self-organization into layered, brain-like architecture; and

[0081] - guiding the maturation of said structures into cell populations exhibiting neuronal and glial phenotypes without inducing pluripotency and while avoiding cellular age erasing.

[0082] It is also an object of the present invention to provide a method of producing a cerebral organoid, comprising

[0083] Culturing olfactory mucosa stem cells that were previously collected from olfactory mucosa of a subject; and

[0084] - Directly or indirectly differentiating said olfactory mucosa stem cells into neurons and glial cells.The present invention also provides a method of producing a cerebral organoid, comprising

[0085] Collecting olfactory mucosa stem cells from olfactory mucosa of a subject;

[0086] Culturing said olfactory mucosa stem cells; and

[0087] - Differentiating said olfactory mucosa stem cells into neurons and glial cells.

[0088] In particular, the invention relates to a method for producing a cerebral organoid, comprising the steps of: (i) culturing olfactory mucosa-derived stem cells obtained from a subject, including healthy or diseased individuals, to form cellular spheres; (ii) aggregating said cellular spheres into organoid-like structures; and (iii) culturing the aggregated structures in a differentiation medium to induce differentiation into neurons and glial cells, including astrocytes and oligodendrocytes.

[0089] The aggregation step (ii) may be performed before or after the initiation of the differentiation step (iii). In addition, step (iii) may further comprise successive culture phases to promote region-specific or cell-type-specific maturation.

[0090] The olfactory stem cells may be obtained from a subject affected by a neurological or neurodegenerative disorder, or from a healthy subject.

[0091] As used herein, “glial cells” or “glia” are non-neuronal cells in the nervous system that provide structural and functional support to neurons. They play essential roles in maintaining homeostasis, protecting neurons, and facilitating signal transmission. Unlike neurons, glial cells do not generate electrical impulses, but they are crucial for overall brain function. Glial cells include astrocytes, oligodendrocytes, ependymal cells and Schwann cells, satellite cells.

[0092] According to the invention, the step of differentiation may be performed directly on the olfactory stem cells, before or after formation of spheroids, or indirectly by transdifferentiating the olfactory stem cells into neuronal stem cells that will differentiate into neurons and glial cells.

[0093] According to the present invention, the method may comprise successive culture phases to promote region-specific or cell-type-specific maturation.

[0094] In an embodiment, the cerebral organoid of the invention comprises neurons selected from motor neurons, sensory neurons, or any neuron population of the central nervous system, and any combination thereof.In a preferred embodiment, the cerebral organoid comprises mature and immature neurons expressing TUJ1 (class III P-tubulin), the neuronal nuclear protein (NeuN) and / or the Microtubule Associated Protein-2 (MAP2).

[0095] The organoid of the invention is preferably deprived of sensory neurons, in particular sensory neurons expressing Olfactory Marker Proteins (OMP) and / or neurons expressing Peripherin.

[0096] In the context of the present invention, "deprived of sensory neurons" means substantially deprived of neurons expressing Olfactory Marker Protein (OMP) and / or neurons expressing Peripherin. Preferably, a cerebral organoid deprived of sensory neurons comprises less than 5% of OMP -positive cells and less than 5% of Peripherin-positive cells, more preferably less than 1% of OMP-positive cells and less than 1% of Peripherin-positive cells, as assessed by immunofluorescence image analysis on organoid cryosections.

[0097] Alternatively or in addition, the cerebral organoid of the invention comprises glial cells selected from astrocytes, oligodendrocytes, ependymal cells, and any combination thereof. For instance, astrocytes may be identified by expression of Glial Fibrillary Acidic Protein (GFAP) and / or SlOOp. Oligodendrocytes may be identified by expression of Olig2, MBP and / or SoxlO.

[0098] Advantageously, the cerebral organoid of the invention comprises at least neurons and astrocytes and / or oligodendrocytes and / or ependymal cells. Preferably, the cerebral organoids of the invention comprise glial cells expressing at least GFAP and Olig2.

[0099] The cerebral organoid of the invention is able to mimic regions of the nervous system, in particular regions of a brain. Advantageously, the nature of the neurons and glial cells and / or their ratio in the organoid are adapted depending on the region of the nervous system, in particular on the region of brain, that the organoid must mimics. In a particularly embodiment, the cultivation step leads to formation of cellular spheres, and the differentiation step is performed before or after aggregation of the cellular spheres into organoids.

[0100] In the context of the invention, “cellular spheres” or “spheroids” refer to free-floating clusters of cells. The cells within the clusters may be from same nature or various natures. In a particular embodiment, the cellular spheres are neurospheres, i.e., free-floating clusters of neural stem cells. The cellular spheres may also be spheres of neurons and / or spheres of glial cells, such as spheres of astrocytes or spheres of oligodendrocytes.

[0101] In an embodiment, the method comprises the steps:

[0102] (i) culturing the olfactory mucosa stem cells to obtain cellular spheres;(ii) aggregating said cellular spheres to form organoids;

[0103] (iii) culturing successively said organoids in adapted culture medium to differentiate cells of the organoids respectively into neurons and glial cells, in particular astrocytes and oligodendrocytes, in order to obtain cerebral organoids.

[0104] In another embodiment, the method comprises the steps:

[0105] (i) culturing the olfactory mucosa stem cells to obtain cellular spheres;

[0106] (ii) culturing said spheres in adapted culture medium to differentiate the cells respectively into neurons and glial cells, in order to obtain spheres of neurons and spheres of glial cells, in particular spheres of astrocytes and spheres of oligodendrocytes;

[0107] (iii) aggregating spheres of neurons and spheres of glial cells to form cerebral organoids.

[0108] For instance, the cellular spheres may be formed by spontaneous aggregation or may be guided by scaffold-based culture systems.

[0109] In another embodiment, the method comprises the steps:

[0110] (i) transdifferentiating the olfactory mucosa stem cells to obtain neuronal stem cells;

[0111] (ii) culturing the neuronal stem cells to obtain neurospheres;

[0112] (iii) aggregating said neurospheres to form neuronal organoids;

[0113] (iv) culturing said neuronal organoids to differentiate the neuronal stem cells into neurons and glial cells, in particular astrocytes and oligodendrocytes.

[0114] In particular embodiments, the culture conditions are adapted to suppress olfactory neuronal identity and to promote central nervous system identity, resulting in cerebral organoids that do not express OMP or Peripherin. In a particular embodiment, the culture conditions are specifically adapted to suppress olfactory sensory neuron identity, resulting in cerebral organoids that do not express OMP and do not express Peripherin.

[0115] In another embodiment, the culture conditions allow to promote maturation of the neurons and inhibit development of olfactory neurons (Lancaster et al., 2013, Nature Methods; Quadrato et al., 2017, Nature; Velasco et al., 2019, Cell).In another embodiment, the culture conditions allow to promote CNS neuron differentiation and the inhibition of the development of olfactory neurons (Chambers et al., 2009, Nature Biotechnology; Shi et al., 2012, Nature Protocols).

[0116] In another embodiment, the culture conditions allow the maintenance and the differentiation of neural stem cells (Reynolds and Weiss, 1992, Science; Gage, 2000, Science).

[0117] In another embodiment, the culture conditions are adapted to enhance glial cell specification, including astrocyte and oligodendrocyte differentiation (Krencik and Zhang, 2011, Nature Protocols; Wang et al., 2013, Cell Stem Cell).

[0118] In another embodiment, the culture conditions are adapted to preserve the biological and epigenetic age of the donor cells throughout the organoid generation process, by avoiding any reprogramming step that would reset the epigenetic clock of the olfactory mucosa stem cells.

[0119] In another embodiment, the culture conditions are adapted to maintain the pathological molecular signature of donor cells obtained from subjects exhibiting a neurological disorder, thereby generating disease-specific cerebral organoids suitable for drug screening and personalized medicine.

[0120] In another embodiment, the culture conditions are applied sequentially during distinct phases of organoid development, comprising a first phase of neural induction, a second phase of organoid assembly and early differentiation, and a third phase of long-term maturation, as exemplified in Example 3.

[0121] In another embodiment, the culture conditions are adapted to promote vascularization of the cerebral organoid, resulting in vascularized cerebral organoids comprising a blood-brain barrier-like structure.

[0122] The above embodiments may be combined in any manner, and the skilled person will understand that any combination of two or more of the above embodiments may be implemented without undue experimentation, the choice of combination depending on the specific application intended and the properties of the cerebral organoid desired.

[0123] Such conditions may comprise, without limitation, activation or inhibition of one or more of the following signaling pathways, or any combination thereof:

[0124] (a) the Notch signaling pathway; (b) the ErbB / Neuregulin signaling pathway; (c) the Hedgehog / Smoothened / Gli signaling pathway; (d) the JAK / STAT signaling pathway; (e) theBMP / SMAD1 / 5 / 8 signaling pathway; (f) the TGFp / Activin / Nodal / SMAD2 / 3 signaling pathway; (g) the Wnt / p-catenin and non-canonical Wnt signaling pathways; (h) the cAMP / PKA / CREB signaling pathway; (i) the IGF / PI3K / AKT / mTOR signaling pathway; (j) the RAS / RAF / MEK / ERK signaling pathway; (k) neurotrophic factor receptor signaling, including TrkA, TrkB, TrkC, p75NTR, GFRa or Ret receptor pathways; (1) thyroid hormone and nuclear receptor signaling; (m) retinoic acid signaling; (n) FGF receptor signaling; (o) EGFR / HER family signaling; (p) ROCK / Rho GTPase signaling; (q) the HGF / c-Met signaling pathway; (r) the SCF / c-Kit signaling pathway; (s) the PDGF / PDGFR signaling pathway; (t) the VEGF / VEGFR signaling pathway; (u) the Hippo / YAP / TAZ signaling pathway; (v) the NFKB signaling pathway; (w) the AMPK / energy sensing pathway; (x) Sirtuin / NAD+ signaling; (y) calcium signaling and CaM Kinase pathways; (z) neurotransmitter signaling pathways, including GABAergic, glutamatergic, dopaminergic and serotonergic pathways; (aa) epigenetic regulatory pathways, including HD AC, histone methyltransferase, histone demethylase, BET bromodomain, and DNMT pathways; (bb) lipid signaling pathways, including SIP, LPA, PGE2 and cannabinoid receptor pathways; (cc) oxygen tension and cellular metabolic pathways; (dd) physical culture parameters, including three-dimensional non-adherent culture format and mechanical stimulation; (ee) extracellular matrix composition and substrate rigidity; (fl culture medium composition, including defined serum-free conditions; (gg) autophagy pathways; (hh) apoptosis pathways; (ii) cell cycle progression pathways; (jj) the Ephrin / Eph receptor signaling pathway; (kk) the Semaphorin / Plexin / Neuropilin signaling pathway; (11) the Netrin / DCC / UNC5 signaling pathway; (mm) immune and inflammatory signaling pathways; or any combination of the above, as would be readily determined by the skilled person.

[0125] Such modulation may be achieved by any means known to the skilled person, including without limitation small molecule activators or inhibitors, recombinant proteins and growth factors, peptides, antibodies or antibody fragments, or genetic or epigenetic tools including mRNA molecules encoding pathway activators or transcription factors, small interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA) mimics or inhibitors, antisense oligonucleotides (ASOs), CRISPR-based gene editing or epigenome editing tools including CRISPRa and CRISPRi approaches, viral vector-mediated gene delivery including lentiviral, adeno-associated viral (AAV) or adenoviral vectors, non-viral delivery systems including lipid nanoparticles (LNPs), base editing or prime editing tools, or any combination thereof. It will be understood that such genetic or epigenetic tools do not constitute a reprogramming step as defined herein, as they do not revert the differentiation state of the olfactory mucosa stem cells to a pluripotent state.The resulting cerebral organoids exhibit central nervous system identity as evidenced by absence of OMP and Peripherin expression and presence of CNS markers including NeuN, MAP2, GFAP and Olig2.

[0126] In a particular embodiment illustrating the conditions listed above, cerebral organoids that are OMP -negative and Peripherin-negative and that exhibit central nervous system identity are obtained by combining activation of the Notch signaling pathway by application of Jaggedl-Fc fusion protein as referred to in condition (a) above, activation of FGF receptor signaling by inclusion of FGF2 as referred to in condition (n) above, activation of neurotrophic factor receptor signaling by inclusion of BDNF, NT-3 and GDNF as referred to in condition (k) above, activation of the JAK / STAT signaling pathway by inclusion of LIF as referred to in condition (d) above, activation of the cAMP / PKA / CREB signaling pathway by inclusion of dibutyryl-cAMP as referred to in condition (h) above, activation of thyroid hormone signaling by inclusion of T3 as referred to in condition (1) above, modulation of cellular metabolism by supplementation with L-ascorbic acid, creatine and sodium pyruvate as referred to in condition (cc) above, use of a three-dimensional non-adherent culture format under orbital agitation as referred to in condition (dd) above, and use of serum-free chemically defined medium comprising B27, N2 and GlutaMAX as referred to in condition (ft) above.

[0127] This combination of conditions, as exemplified in Example 3, results in cerebral organoids derived from olfactory ectomesenchymal stem cells and / or olfactory basal stem cells that are OMP -negative and Peripherin-negative and that express NeuN, Tujl, GFAP and / or Olig2, confirming central nervous system identity. The skilled person will appreciate that other combinations of conditions listed in (a) to (mm) above may equally be applied to achieve the same result, without undue experimentation.

[0128] In a particular embodiment, the cerebral organoid of the invention is generated from a combination of olfactory basal stem cells and olfactory ectomesenchymal stem cells co-cultured together to generate a cerebral organoid comprising the combined differentiation potential of both cell populations.

[0129] In another embodiment, cerebral organoids are generated in parallel from olfactory mucosa stem cells of a healthy subject and from a subject exhibiting a neurological disorder, to enable direct comparison of molecular signatures between healthy and pathological organoids.

[0130] In another embodiment, the olfactory mucosa stem cells are derived from a non-human mammal, in particular from a rodent or a non-human primate, to generate cerebral organoids for preclinical research applications, as exemplified in Example 2.11

[0131] In another embodiment, the olfactory mucosa stem cells are used at a defined passage number to preserve the biological age characteristics of the donor cells and to ensure reproducibility of the organoid generation process.

[0132] In another embodiment, the cerebral organoids of the invention are co- cultured with additional cell types, including without limitation microglia, immune cells, or cells derived from other neural regions, to generate more complex and physiologically relevant brain organoid models. In another embodiment, the cerebral organoids of the invention are generated in a scalable format, including without limitation spinner flasks, rotating bioreactors, microwell arrays, or automated culture platforms, to enable high-throughput production for drug screening or clinical applications.

[0133] The present invention thus allows to produce cerebral organoids from adult olfactory mucosa-derived stem cells, that are easily accessible and harvested without invasive procedures. Furthermore, the production of the present invention does not involve genetic reprogramming, thereby preserving the donor's biological and epigenetic age. The cerebral organoids according to the invention show mature neural cell types (e.g., mature neurons, glial cells). It is particularly suited for generating personalized adult brain models, enabling the study of age-related neurological diseases, neurodegeneration, or brain aging processes in vitro.

[0134] The olfactory system is widely recognized as a unique gateway to understanding neurological disorders, given its direct link to the brain and its sensitivity to pathological changes. Notably, olfactory dysfunction often appears early, and in some cases as a prodromal symptom, across a range of neurological conditions, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and schizophrenia.

[0135] Unlike iPSC-derived cerebral organoids, in which the reprogramming process resets the epigenetic clock and eliminates age-related molecular signatures, one of the main advantages of the method of producing cerebral organoids according to the invention is that said method is free of any reprograming step that would lead to a loss of cellular aging specificities. This may be of particular interest to study neurological disorders, in particular neurodegenerative diseases. Indeed, the method of producing cerebral organoids of the present invention preserves the pathological molecular signature observed in the stem cells of the subject..

[0136] The olfactory mucosa stem cells, unlike iPSC, retain their original aging state and epigenetic modifications, faithfully replicating the molecular changes observed in the brains of patients with neurodegenerative diseases like Alzheimer’s, or psychiatric disorders, such asschizophrenia, or aging. Therefore, on the contrary to cerebral organoids produced from iPSC, the use of olfactory mucosa stem cells to produce cerebral organoids allows to preserve the molecular signature of the cells of the subject. It is of particular interest to manufacture cerebral organoids of a subject with neurological disorder, such as neurodegenerative disease.

[0137] Thus, in a particular embodiment, the olfactory stem cells are obtained from a subject exhibiting a neurological disorder, in particular a neurodegenerative disorder.

[0138] In an embodiment, the olfactory stem cells are collected or were previously collected from a subject exhibiting Alzheimer’s disease.

[0139] Cerebral organoid

[0140] The inventors have developed a cerebral organoid from olfactory mucosa stems cells that presents a central nervous system identity.

[0141] It is a further object of the present invention to provide a cerebral organoid obtainable by the method of the present invention.

[0142] It is also an object of the present invention to provide cerebral organoid comprising mature neurons expressing TUJ1 (class III -tubulin), the neuronal nuclear protein (NeuN) and / or the Microtubule Associated Protein-2 (MAP2) and glial cells selected from astrocytes and / or oligodendrocytes. Preferably, the cerebral organoid of the invention comprises glial cells expressing at least GFAP and / or Olig2, more preferably both GFAP and Olig2. The cerebral organoid may further comprise neural stem cells.

[0143] Importantly, the expression of CNS neuronal markers (e.g., NeuN, MAP2, DCX, TUJ1) and glial markers (e.g., GFAP and / or Olig2) demonstrates that the organoids of the invention acquire a central nervous system identity rather than an olfactory or peripheral nervous system identity.

[0144] Advantageously, the cerebral organoid of the invention refers to a non-olfactory three-dimensional neural organoid derived from olfactory mucosa stem cells, comprising neuronal and glial cell types exhibiting CNS-like molecular features, and being substantially devoid of olfactory sensory neuron identity.

[0145] In a particular embodiment, the organoid of the invention comprises immature and mature neurons expressing at least NeuN, MAP2, and TUJ1, astrocytes expressing GFAP and oligodendrocytes expressing Olig2.The organoid may further comprise neural stem cells.

[0146] Advantageously, the cerebral organoid is deprived of neurons expressing Olfactory Marker Proteins (OMP) and / or neurons expressing Peripherin. Preferably, the organoid of the invention does not significantly express both OMP and Peripherin. This quasi absence of olfactory markers confirms that the organoids of the invention are cerebral organoids that do not retain olfactory identity.

[0147] The cerebral organoid may be obtained from olfactory mucosa stem cells, preferably selected from olfactory basal stem cells, olfactory ectomesenchymal stem cells or combination thereof.

[0148] In a particular embodiment, the olfactory mucosa stem cells are from a subject exhibiting a neurological disorder, in particular a neurodegenerative disorder or a neuropsychiatric disorder. More particularly, the olfactory mucosa stem cells may be selected from a subject exhibiting Alzheimer's disease, Parkinson's disease, schizophrenia, or bipolar disorder.

[0149] Advantageously, the cerebral organoid of the invention, obtained from olfactory mucosa stem cells of a subject retain the pathological molecular signature observed in the stem cells of the subject. Indeed, the olfactory stem cells used for producing the cerebral organoid do not require reprogramming process. It allows to substantially preserve the biological and epigenetic age of the donor cells. It is particularly suited for generating personalized adult brain models, enabling the study of age-related neurological diseases, neurodegeneration, or brain aging processes in vitro. For instance, the cerebral organoid obtained may be used as a model of the disorder of the patient, for instance to test drug’s efficacy.

[0150] In another particular embodiment, the cerebral organoid is generated from olfactory mucosa stem cells of a healthy subject, i.e., who does not exhibit neurological disorder.

[0151] Vascularized cerebral organoids

[0152] It is a further object of the present invention to provide organoids with a blood-brain barrier (BBB) structure, i.e., a vascular organoid. In addition, it is a further object of the present invention to provide cerebral organoids integrating a BBB structure.

[0153] The blood-brain barrier is a selective, semipermeable barrier formed by tightly joined endothelial cells lining the brain’s capillaries. It separates the circulating blood from the brain’s extracellular fluid, maintaining a stable environment for neural function. The BBB is supported by astrocyte end-feet, pericytes, and a basement membrane. Its main functions include protecting the brain from toxins and pathogens, regulating the transport of essential nutrients,preventing fluctuations in blood composition from disrupting neural activity, and restricting the entry of potentially harmful substances. While it effectively shields the brain, the BBB also poses a challenge for delivering drugs to treat central nervous system diseases. It is thus of particular importance to develop cerebral organoids with BBB structure, in order to enhance the physiological relevance of these models for studying human brain development, disease, and drug responses. Traditional cerebral organoids lack vascularization and a functional BBB, which limits their ability to mimic the brain’s complex microenvironment. Incorporating a BBB allows researchers to study how nutrients, drugs, and immune cells cross into the brain, and how barrier dysfunction contributes to neurological disorders like Alzheimer's, multiple sclerosis, or stroke. It also enables more accurate drug permeability testing, improving the prediction of a compound’s ability to reach the brain. Furthermore, BBB-integrated organoids can model neurovascular interactions, offering insight into how the brain and its vasculature co-develop and respond to disease.

[0154] By working on the development of vascularized organoids, the inventors have discovered that mesenchymal stem cells, and in particular ectomesenchymal stem cells, may be used to vascularize organoids. The inventors have further shown that these ectomesenchymal stem cells can (i) transdifferentiate into CD31+ / VE-cadherin+endothelial cells under VEGF and bFGF stimulation and (ii) adopt a NG2+ / PDGFR-P+pericyte-like phenotype capable of stabilizing nascent vessels, thereby supplying both luminal and mural components of the BBB.

[0155] It is therefore a further object of the present invention to provide a model of vascularization network, in particular of blood brain barrier (BBB), obtained from peripheral vascular endothelial cells, different from brain endothelial cells. Said model of BBB may further include pericytes or progenitors thereof.

[0156] According to a particular embodiment, ectomesenchymal stem cells may be used, either alone or in combination with endothelial cells (ECs) co-isolated from the same biopsy or obtained from peripheral vasculature (e.g., aorta, artery, vein, micro-vessels, etc.), to develop vascularization.

[0157] The present invention thus provides a vascular organoid derived from olfactory mucosa-derived cells of a mammalian subject, obtained without cellular reprogramming to a pluripotent state, comprising pericyte-like cells derived from OE-MSCs expressing one or more markers selected from NG2, PDGFR-P and a-SMA, optionally in combination with endothelial cells derived from OE-MSCs by trans differentiating and / or isolated directly from the olfactory mucosa of the same subjectThe present invention proposes to use peripheral vascular endothelial cells in combination with ectomesenchymal stem cells to develop a model of BBB.

[0158] In particular, said model of BBB may be obtained from a combination of peripheral vascular endothelial cells and ectomesenchymal stem cells. For instance, said cells may be obtained from olfactory epithelium.

[0159] Preferably, the ectomesenchymal stem cells are from the olfactory mucosa.

[0160] Advantageously, said ectomesenchymal stem cells exhibit the intrinsic cellular age of the subject. The use of said ectomesenchymal stem cells allows the generation of BBB organoids without erasing the donor cells' age-related identity, thus faithfully modeling the adult BBB, rather than an embryonic or developmental stage.

[0161] It is a further object of the present invention to provide a method of producing a vascular organoid from olfactory mucosa-derived cells of a subject, comprising differentiating olfactory ectomesenchymal stem cells (OE-MSCs) under angiogenic conditions to obtain pericyte-like cells expressing one or more markers selected from NG2, PDGFR-P and a-SMA, optionally in combination with endothelial cells derived from OE-MSCs by trans differentiating and / or isolated directly from the olfactory mucosa of the same subject, and assembling said cells into a three-dimensional vascular organoid structure, said method being deprived of a reprogramming step. In a particular embodiment, both the cerebral organoid and the BBB organoid are obtained from ectomesenchymal stem cells derived from the olfactory mucosa of a subject. That is to say that a single biopsy of olfactory mucosa of a subject may provide all the necessary cells to develop the cerebral organoid and vascularization thereof. Indeed, olfactory mucosa is a vascularized tissue from which ECs can be derived, as well as ectomesenchymal stem cells and if need be basal stem cells.

[0162] Cerebral organoids of the invention may be combined with a vascular component derived from OE-MSCs or co-isolated from the same olfactory mucosa biopsy, under conditions promoting angiogenesis and neurovascular interactions, to generate vascularized cerebral organoids, using methods as would be determined by the skilled person.

[0163] The present invention thus provides a method of producing a vascularized cerebral organoid from olfactory mucosa-derived cells of a subject, comprising: (i) generating a cerebral organoid as exposed above; (ii) generating a vascular organoid as exposed above; (iii) assembling said cerebral organoid and said vascular organoid by sequential fusion at any stage of organoid development, or by simultaneously co-culturing cells destined for neural and vasculardifferentiation from the outset in a single culture vessel, or by embedding the cerebral organoid within a vascular matrix comprising extracellular matrix components and vascular cells, or by perfusion of the cerebral organoid through microchannels comprising vascular cells, or by any other method promoting neurovascular interactions as would be determined by the skilled person, to obtain a vascularized cerebral organoid.

[0164] In a particular embodiment, the sequential fusion comprises co-culturing a pre-formed cerebral organoid and a pre-formed vascular organoid at any stage of their respective development in physical proximity under conditions promoting spontaneous organoid fusion and neurovascular assembly.

[0165] In another embodiment, the simultaneous assembly comprises co-culturing OE-MSCs destined for neural differentiation and cells destined for vascular differentiation from the outset in a single culture vessel under conditions allowing spontaneous co-organization of both neural and vascular components into a vascularized cerebral organoid.

[0166] In another embodiment, the assembly comprises embedding the cerebral organoid within a vascular matrix comprising extracellular matrix components and vascular cells derived from OE-MSCs and / or isolated from the olfactory mucosa of the same subject, including without limitation hydrogel-based matrices, bioprinted scaffolds, or any biocompatible three-dimensional matrix supporting vascular cell growth and neurovascular interactions.

[0167] In another embodiment, the assembly comprises perfusion of the cerebral organoid through microchannels lined with endothelial cells derived from OE-MSCs by transdifferentiating and / or isolated from the olfactory mucosa of the same subject, under defined flow conditions promoting vascular lumen formation and neurovascular interactions.

[0168] In a particular embodiment, the cerebral organoid and the vascular organoid are both derived from cells of the same donor subject, thereby generating a fully autologous vascularized cerebral organoid in which both components preserve the biological age and molecular characteristics of the donor without reprogramming.

[0169] For instance, vascularized cerebral organoids may be generated from olfactory mucosa-derived stem cells according to the following general approach.

[0170] Olfactory ectomesenchymal stem cells (OE-MSCs) isolated are processed to generate two distinct cellular components: a neural organoid component derived from OE-MSCs or olfactory basal stem cells according to the present invention, and a vascular component comprisingendothelial cells derived from OE-MSCs by transdifferentiating under angiogenic conditions, or co-isolated from the same olfactory mucosa biopsy.

[0171] The vascular and neural components are subsequently assembled by co-culture under conditions promoting angiogenesis and neurovascular interactions, including without limitation supplementation with vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF-BB), and basic fibroblast growth factor (bFGF).

[0172] The resulting vascularized cerebral organoids may be characterized by immunofluorescence for endothelial cell markers, pericyte markers, and tight junction proteins, as well as by functional permeability assays, using methods and markers appropriate to the experimental context and as would be determined by the skilled person.

[0173] In a particular embodiment, both the neural and vascular components are derived from cells of the same donor subject, thereby preserving the biological age and molecular characteristics of the donor in both components.

[0174] The vascularized cerebral organoid of the invention may be derived from cells of a subject exhibiting a neurological disorder, and the organoid retains the pathological molecular signature of said subject in both the neural and vascular components.

[0175] Neuroimmune organoids

[0176] Cerebral organoids of the invention may further be co-cultured with microglial cells and / or immune cell populations including without limitation peripheral blood mononuclear cells (PBMCs), monocytes, macrophages, T lymphocytes, B lymphocytes, natural killer cells, or dendritic cells, derived from the same donor or from independent sources, to generate more complex and physiologically relevant brain organoid models incorporating neuroinflammatory and neuroimmune components. .

[0177] For instance, the microglial cells, as the resident immune cells of the central nervous system, may be incorporated into the cerebral organoids of the invention to recapitulate the neuroglia-immune interactions of the adult human brain. Additional immune cell populations suitable for co-culture include without limitation peripheral blood mononuclear cells (PBMCs), monocytes, macrophages, T lymphocytes, B lymphocytes, natural killer (NK) cells, dendritic cells, or any combination thereof.

[0178] Such immune cells may be derived from the same donor subject as the olfactory mucosa stem cells used to generate the cerebral organoid, enabling fully autologous patient-specificneuroimmune models, or may be obtained from healthy donors or from subjects exhibiting neurological or inflammatory disorders.

[0179] Microglial cells may be derived from olfactory mucosa stem cells by directed differentiation, from induced pluripotent stem cells, or obtained from primary tissue sources. Other immune cell populations may be obtained from peripheral blood or other primary tissue sources including without limitation bone marrow or spleen, and incorporated into the cerebral organoids of the invention at defined stages of organoid maturation according to methods known to the skilled person. The resulting organoids may be characterized for microglial identity markers, immune cell activation states, cytokine release profiles, and neuroinflammatory responses to pharmacological stimuli or pathological triggers, using methods and markers as would be determined by the skilled person.

[0180] Uses of cerebral organoids

[0181] The organoids of the present invention may be used for medical and therapeutic purposes. In particular, the organoids may be used for modeling of a neurological disorder, such as a neurodegenerative disease, or psychiatric disorders, such as schizophrenia. Indeed, the cerebral organoids according to the present invention, obtained from olfactory mucosa stem cells of a subject with a neurodegenerative disease show same pathological molecular signature as observed in the brains of said subject, despite cerebral organoids obtained from iPSC.

[0182] In a particular embodiment the cerebral organoid is generated from olfactory mucosa stem cells of a subject exhibiting a neurological disorder, in particular a neurodegenerative disorder. For instance, the cerebral organoid is generated from olfactory mucosa stem cells of a subject exhibiting an Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, or amyotrophic lateral sclerosis (ALS).

[0183] Interestingly, by performing biopsies at different stages of the disease over a given period, it is possible to study the subtle molecular changes associated with the disease's progression over time.

[0184] The organoids of the present invention may be further used for screening for a prophylactic or therapeutic drug. This may be of particular interest for screening for a prophylactic or therapeutic drug for a neurological disorder.In one embodiment, the present invention provides a screening method for a therapeutic drug for a neurological disorder, in particular a neurodegenerative disease or a neuropsychiatric disorder.

[0185] In particular, the present invention provides a screening method for a therapeutic drug for Alzheimer's disease, Parkinson's disease, schizophrenia, or bipolar disorder.

[0186] According to the invention, the screening method may include a step of culturing the abovedescribed cerebral organoid in the presence of a test substance; and a step of assessing the effects of the test substance on the cerebral organoids.

[0187] For instance, the cerebral organoid is obtained from stem cells of a subject having a neurodegenerative disease or neuropsychiatric disorder. The screening method may include a step of culturing said cerebral organoid in the presence of a test substance; and a step of assessing the effects of the test substance on the pathological cerebral organoids.

[0188] In a particular embodiment, the cerebral organoid is obtained from stem cells of a subject having Alzheimer’s disease. The screening method may include a step of culturing said cerebral organoids in the presence of a test substance; and a step of assessing the effects of the test substance on said pathological cerebral organoids.

[0189] In a particular embodiment, the cerebral organoid is obtained from stem cells of a healthy subject.

[0190] More generally, the cerebral organoids of the present invention may be used for medical and research purposes, such as prevention, clinical trial stratification, diagnosis, prediction of disease progression, precision medicine, toxicity assessment, studying aging and brain function, developmental biology, or early diagnosis applications, etc.

[0191] In particular embodiments, the cerebral organoids of the present invention may be used for patient stratification, biomarker discovery, prevention, or early diagnosis in the context of clinical trials or personalized therapeutic interventions. Alternatively or in addition, the organoids may be used as biological models in neuroscience, developmental biology, regenerative medicine, pharmacology, environmental research, preventive medicine, or educational settings.

[0192] In a particular embodiment, the cerebral organoid is obtained from olfactory mucosa stem cells of aged, young, or healthy subjects for studying aging processes, cellular senescence, prevention of neurodegeneration, or neurodegeneration mechanisms.In a particular embodiment, the cerebral organoid are used for screening a candidate compound for prophylactic or therapeutic treatment of a disorder of the central nervous system.

[0193] In a particular embodiment, the cerebral organoid are generated under xeno-free, chemically defined conditions suitable for clinical-grade production.

[0194] Moreover, the cerebral organoids generated according to the invention, including vascularized cerebral organoids, may be integrated into microfluidic devices or organ-on-chip platforms to enable dynamic culture conditions and real-time monitoring of organoid development, neuronal activity, and response to pharmacological compounds. In a particular embodiment, cerebral and vascular organoids are cultured in adjacent compartments of a microfluidic device connected by a perfusion channel, allowing controlled exchange of culture medium and pharmacological agents between the two compartments under defined flow conditions. Such microfluidic integration may enable physiological perfusion of the organoids, improved oxygenation and nutrient delivery, real-time monitoring of organoid viability and function, and assessment of drug permeability and neurotoxicity under dynamic conditions, using methods and configurations as would be determined by the skilled person.

[0195] The cerebral organoids of the invention may also be combined with organoids of other neural regional identities to generate multi-region brain assembloids for the study of inter-regional neural connectivity and communication in vitro, using methods as would be determined by the skilled person.

[0196] The olfactory mucosa stem cells, or the cerebral organoids obtained from said stem cells, may be cryopreserved for long-term storage and future use, enabling the establishment of patient-derived biobanks for longitudinal studies and large-scale applications, using methods as would be determined by the skilled person.

[0197] The cerebral organoids of the invention may be produced at a scale level using spinning bioreactors, microwell arrays, or automated culture platforms, to enable high-throughput drug screening applications, using methods as would be determined by the skilled person.

[0198] The olfactory mucosa stem cells or neural cells derived from cerebral organoids of the invention may be used for cell therapy applications including transplantation into the nervous system of a subject in need thereof, using methods as would be determined by the skilled person.

[0199] The cerebral organoids according to the invention may be used for the assessment of neurotoxicity of chemical compounds, pharmaceutical agents, or environmental pollutants,providing a human-relevant alternative to animal models, using methods as would be determined by the skilled person.

[0200] The cerebral organoids of the invention may be produced in miniaturized formats compatible with 96-well or 384-well plates for high-throughput screening of compound libraries, using methods as would be determined by the skilled person.

[0201] The cerebral organoids generated from olfactory mucosa stem cells of subjects exhibiting neuropsychiatric disorders including schizophrenia or bipolar disorder may be used to model the molecular and cellular alterations associated with these conditions and to screen for prophylactic or therapeutic compounds, using methods as would be determined by the skilled person.

[0202] The cerebral organoids generated from olfactory mucosa stem cells of donors of different ages may be used to study age-related molecular and cellular changes in the human brain in vitro, and to identify biomarkers of brain aging and neurodegeneration, using methods as would be determined by the skilled person.

[0203] The cerebral organoids generated from olfactory mucosa stem cells obtained by minimally invasive nasal biopsy may be used to identify early molecular biomarkers of neurological disorders including Alzheimer's disease and Parkinson's disease, prior to clinical symptom onset, using methods as would be determined by the skilled person.

[0204] The cerebral organoids generated from olfactory mucosa stem cells of a specific patient may be used to assess individual pharmacological responses to existing or candidate therapeutic agents prior to clinical prescription, enabling personalized medicine approaches for neurological disorders, using methods as would be determined by the skilled person.

[0205] EXAMPLES

[0206] Figure 1 schematically illustrates the main steps of generating cerebral organoids from a patient's nasal biopsy, according to the invention. The procedure begins with nasal endoscopy to collect tissue from the olfactory region. The sample undergoes biopsy and is processed for cell isolation and expansion. The resulting stem cells are cultured to form spheroids, which are subsequently matured into cerebral organoids.

[0207] Example 1: Generation of cerebral organoids from olfactory stem cells from patients with Alzheimer’s disease and from a healthy subjectSample preparation

[0208] The samples are prepared according to a protocol adapted from the protocol described in Jaloux, C. et al. (2022) (“Clinical-grade human nasal olfactory stem cells (OE-MSCs) from olfactory mucosa for cell therapy in neurological diseases”. Journal of Clinical Investigation.).

[0209] Tissue Preparation and Handling:

[0210] Two sterile cryotubes for the olfactory mucosa biopsies are prepared containing: T-Store + 1% N2 + 2 % B27 (without vitamin A).

[0211] The biopsy is collected in this sterile container with cold medium.

[0212] Under sterile conditions, the biopsy tissue is minced into pieces approximately 1 mm in size to ensure effective enzyme penetration.

[0213] One of the pieces is cut and placed it in a cryotube containing Qiazol. Keep it at -80°C.

[0214] The rest is separated into two groups:

[0215] - Two pieces are dissociated enzymatically and mechanically. Then, they will be seeded into specific culture media, each optimized to promote the proliferation of the corresponding cell types.

[0216] - Three pieces are separated and purified by magnetic cell sorting using MACS system (Miltenyi Biotec, Germany).

[0217] Isolation of olfactory ectomesenchymal stem cells (OE-MSCs)

[0218] The OE-MSCs are isolated according to the protocol described in Jaloux, C. et al. 2022 and Girard SD, et al. 2011. (Isolating nasal olfactory stem cells from rodents or humans. J Vis Exp.

[0219] 2011 Aug 22).

[0220] 1) Enzymatic Digestion of Lamina Propria:

[0221] A 60mm dish containing 5 mL DMEM / F12 and Dispase II (2.4 lU / mL) is prepared.

[0222] The minced tissue is incubated in Dispase II for 1 hour at 37°C. Dispase II selectively loosens the epithelial layer from the connective tissue beneath (lamina propria).The epithelial layer containing basal cells is carefully separated from the lamina propria using fine forceps under a dissection microscope.

[0223] With the epithelial layer removed, the lamina propria is digested with Collagenase I (0.25%) diluted in HBSS for 1-2 hours at 31° C.

[0224] This digestion releases ecto-mesenchymal stem cells from the surrounding connective tissue.

[0225] the medium and the dissociated tissue are transferred into a 15 mL-tube.

[0226] 2) Filtration and Isolation:

[0227] 5 mL PBS are added to neutralize collagenase activity, then mixed.

[0228] The suspension is filtered through a 70 pm strainer to remove tissue debris.

[0229] The filtrate is centrifugated and resuspended in MSC medium.

[0230] Mesenchymal stem cells medium (MSC medium): DMEM / F12, 10 % FBS, 1% P / S

[0231] 3) Plating and Culture:

[0232] Cells are plated in adherent plates at a density of : 5000 cells / cm2

[0233] Table 1: Cell culture

[0234] Culture plate Surface area (cm2) Seeding density (per well) 24-well 1.9 9500 cells

[0235] 12-well 3.5 17500 cells

[0236] 6-well 9.6 48000 cells

[0237]

[0238] T25 flask 25 125000 cells

[0239] The cells are cultured at 37°C with 5% CO2.

[0240] Every 2-3 days, the medium is collected, washed with PBS and fresh MSC medium is added.

[0241] 4) Expansion and Passaging:

[0242] When cells reach 80-90% confluency, they are detached with 0.05% trypsin-EDTA, centrifuged, and replated at a lower density for further expansionImmunohistochemistry for 2D Cultures and 3D Organoids

[0243] Sample Preparation: For 2D cultures, ectomesenchymal stem cells, basal stem cells, and olfactory mucosa-derived cells were seeded onto glass coverslips pre-coated with poly-L-omithine (10 pg / mL) and laminin (5 pg / mL). For 3D cultures, organoids derived from ectomesenchymal stem cells or basal olfactory stem cells were collected at differentiation time points (typically between day 14 and day 30).

[0244] Organoid Embedding and Cryosectioning: After fixation, organoids were embedded in Optimal Cutting Temperature (OCT) compound, frozen, and stored at -80°C. Organoids were sectioned into 10-20 pm thick slices using a cryostat (e.g., Leica CM series) and mounted onto Superfrost Plus glass slides. Cryosections were air-dried before proceeding to immunohistochemical staining.

[0245] Fixation: Cells on coverslips and cryosections of organoids were fixed with 4% paraformaldehyde (PF A) in phosphate-buffered saline (PBS) for 15 minutes at room temperature, followed by three washes in PBS.

[0246] Staining Procedure: Samples were permeabilized with PBS containing 0.3% Triton X-100 for 15 minutes and blocked with PBS containing 5% donkey serum and 0.1% Triton X-100 for 1 hour. Primary antibodies were incubated overnight at 4°C in blocking buffer. Antibodies targeted markers such as Nestin, CD73, S100A4, Tujl, Sox2, and K14. Secondary antibodies conjugated to Alexa Fluor dyes were applied for 1 hour at room temperature. Nuclear counterstaining was performed with Hoechst 33342 (1 pg / mL).

[0247] Mounting and Imaging: For 2D cultures, coverslips were mounted onto microscope slides using Fluoromount-G. Cryosections of organoids were mounted directly after staining using Fluoromount-G or equivalent antifade mounting medium. Samples were imaged using a confocal laser scanning microscope at magnifications of 20*, 40*, or 63 x depending on experimental needs.

[0248] Image Analysis: Image analysis was conducted using ImageJ (Fiji), including fluorescence intensity quantification, signal co-localization studies, and structural assessment. Spatial compartmentalization between progenitor cells (e.g., Sox2+) and differentiated neurons (e.g., Tuj 1+) was specifically analyzed in 3D organoid cryosections.

[0249] 2. Direct differentiation

[0250] Neural induction and NSC niche establishment (Days 0-4)Cells were seeded in ultra-low attachment plates to promote 3D aggregation. For niche structuring, cultures were either uncoated or coated with Jaggedl-Fc (2 pg / mL) to activate the Notch signaling pathway and maintain neural stem cell (NSC) quiescence. From day 0 to day 2, the induction medium consisted of Neurobasal medium supplemented with B27 without vitamin A, EGF (20 ng / mL), bFGF (20 ng / mL), and heparin (2 pg / mL). Cultures were maintained under static conditions at 37°C in 5% CO2.

[0251] Organoid formation and proliferation (Days 4 14)

[0252] Neural progenitor expansion and early organoid formation were initiated by continued culture in Neurobasal + B27 (no VitA), heparin (2 pg / mL), and decreasing concentrations of growth factors. From day 4 to 10, the medium was supplemented with EGF (10 ng / mL) and bFGF (10 ng / mL), followed by bFGF alone (5 ng / mL) from day 10 to 14.

[0253] Organoid differentiation (Days 14 37)

[0254] Spontaneous neuronal and glial differentiation of organoids was initiated on day 14. Organoids were cultured in Neurobasal medium supplemented with B27 and BDNF (20 ng / mL) with low concentration of bFGF (Ing / ml).

[0255] Results

[0256] The cerebral organoids as discussed below and illustrated by the figures, were obtained by direct differentiation, according to the protocol described above.

[0257] Characterization of human ectomesenchymal stem cells (ectoMSCs) revealed expression of markers reflecting both their mesenchymal (CD73, S100A4) and neural crest-related (Nestin) origin (Figure 4). This hybrid phenotype aligns with previous studies showing that ectoMSCs retain neurogenic potential while maintaining mesenchymal characteristics. Their adherence, spindle-shaped morphology, and marker profile collectively confirm their identity as ectomesenchymal stem cells suitable for 2D and 3D differentiation protocols.

[0258] The ability of healthy donor-derived ectoMSCs to form 3D structures was then explored (Figure 5). Upon transfer to non-adherent conditions, cells formed uniform spheroids that progressively fused into larger, compact organoids. Over a two-week period, these organoids exhibited smooth contours and dense internal structure, indicative of high viability and coordination of cellular expansion. These results demonstrate the inherent capacity of ectoMSCs to undergo self-aggregation, morphogenesis, and long-term structural maintenance, key features required for organoid-based modeling. Strikingly, ectoMSCs derived from Alzheimer’s disease patientsretained the ability to generate spheroids and mature organoids (Figure 6). Despite the pathological background, these cells successfully formed uniform aggregates, fused into cohesive structures, and established a proliferative 3D architecture over time. This underscores the robustness of ectoMSC-based organoid systems and their potential use in disease modeling and personalized therapeutic screening.

[0259] After 14 days of differentiation, organoids generated from healthy donor ectoMSCs exhibited widespread expression of the neuronal marker Tujl (Figure 7).

[0260] Immunostaining revealed dense, neuron-rich zones, with organized extensions and well-defined nuclear architecture. These results confirm that ectoMSCs can reproducibly generate neuronally differentiated organoids under defined culture conditions. The data reinforce their use as a versatile tool for modeling neurodevelopment and disease.

[0261] Example 2: Generation of cerebral organoids from olfactory stem cells of rodent

[0262] Isolation of Mouse and Rat Olfactory Mucosa

[0263] Animals: Adult C57BL / 6 mice (8-12 weeks old) and adult Sprague-Dawley rats (8-12 weeks old) were used for olfactory mucosa isolation. All experimental procedures involving animals were conducted in accordance with institutional animal care and use guidelines, and with prior approval from the institutional ethics committee.

[0264] Tissue Collection: Animals were euthanized by cervical dislocation (mice) or by an overdose of anesthetic followed by decapitation (rats), according to approved protocols. The heads were rapidly removed and immersed in cold sterile phosphate-buffered saline (PBS). Under a dissection microscope, the lower jaw, brain, and overlying tissues were carefully excised to expose the nasal cavity.

[0265] Dissection of Olfactory Mucosa: The olfactory mucosa, identifiable by its location on the dorsal and lateral aspects of the nasal turbinates and the superior portion of the nasal septum, was gently dissected using fine forceps and micro-scissors. Care was taken to remove the mucosa without damaging the underlying bone structures. The isolated tissues were immediately transferred into cold sterile PBS.

[0266] Tissue Dissociation: Collected olfactory mucosae were mechanically dissociated by gentle trituration through fire-polished glass pipettes. For single-cell preparation, enzymatic digestion was performed using a mixture of dispase (2 U / mL) and collagenase type I (1 mg / mL) diluted in PBS, incubated for 30 minutes at 37°C under gentle agitation. After enzymatic digestion, thecell suspension was filtered through a 70 pm nylon mesh to remove debris, then centrifuged at 300 x g for 5 minutes at 4°C.

[0267] Cell Resuspension and Culture: The resulting cell pellet was resuspended in Neurobasal medium supplemented with B27 (minus vitamin A), N2 supplement, epidermal growth factor (EGF, 20 ng / mL), basic fibroblast growth factor (bFGF, 20 ng / mL), and heparin (2 pg / mL). Cells were either plated on culture dishes coated with poly-L-omithine and laminin for adherent culture, or seeded into ultra-low attachment plates for 3D spheroid or organoid culture, depending on experimental following protocols as described below for human organoid formation.

[0268] Enrichment Step: For further enrichment of specific subpopulations, such as basal progenitor cells or ectomesenchymal stem cells, differential adhesion methods, fluorescence-activated cell sorting (FACS), or magnetic-activated cell sorting (MACS) using specific surface markers could be employed, following protocols previously described for human cell processing.

[0269] Results

[0270] Same protocols of organoid manufacturing and immunohistochemistry as described in Example 1 were implemented.

[0271] The phenotype of basal stem cells derived from the adult mouse olfactory mucosa was first examined (Figure 2). Cells cultured under adherent conditions expressed both cytoskeletal markers associated with basal epithelial cells (K14) and the transcription factor Sox2, commonly used to identify neural progenitor cells. Co-expression of these markers suggests that these basal cells maintain a dual identity — epithelial and progenitor — consistent with their in vivo role as a source of neurogenic and supporting cells in the olfactory epithelium. This supports their potential as starting material for neural reprogramming or organoid development.

[0272] Organoids generated from mouse olfactory stem cells after 14 days of differentiation were analyzed by immunohistochemistry (Figure 3). These organoids exhibited robust expression of Tuj 1, a marker of post-mitotic neurons, and retained Sox2-positive zones, likely corresponding to undifferentiated or progenitor-rich regions. The clear compartmentalization between Tujl-and Sox2-positive domains suggests an organized differentiation process within the 3D environment. This structural arrangement is reminiscent of early neuroepithelial patterning and confirms that olfactory mucosa-derived stem cells can self-organize into layered, heterogeneous neural tissues.Example 3: Generation of long-term cerebral organoids from olfactory mucosa stem cells — 90-day protocol

[0273] Culture media

[0274] Neural induction medium (Days 0-14):

[0275] Neurobasal medium (Thermo Fisher Scientific) supplemented with B27 without vitamin A (2%, Thermo Fisher Scientific), GlutaMAX (1%, Thermo Fisher Scientific), Antibiotic-Antimycotic (1%, Thermo Fisher Scientific), recombinant human EGF (20 ng / mL, PeproTech), recombinant human bFGF (20 ng / mL, PeproTech), and heparin (2 pg / mL, Sigma-Aldrich).

[0276] Organoid differentiation medium (Days 14-42):

[0277] A 1:1 mixture of Neurobasal medium and DMEM / F12 (Thermo Fisher Scientific), supplemented with B27 without vitamin A (2%), N2 supplement (1%, Thermo Fisher Scientific), GlutaMAX (1%), Antibiotic-Antimycotic (1%), insulin (25 pg / mL. Sigma-Aldrich), 2-mercaptoethanol (0.1 mM, Sigma- Aldrich), MEM non-essential amino acids (1%, Thermo Fisher Scientific), recombinant human EGF (20 ng / mL), and recombinant human bFGF (20 ng / mL).

[0278] Maturation medium (Days 42-90):

[0279] Neurobasal A medium (Thermo Fisher Scientific) supplemented with B27 with vitamin A (2%, Thermo Fisher Scientific), N2 supplement (1%), GlutaMAX (1%), Antibiotic-Antimycotic (1%), recombinant human BDNF (20 ng / mL, PeproTech), recombinant human NT-3 (10 ng / mL, PeproTech), recombinant human GDNF (10 ng / mL, PeproTech), Leukemia Inhibitory Factor (LIF, 10 ng / mL, Merck), L-ascorbic acid (200 pM, Sigma- Aldrich), creatine (5 mM, Sigma- Aldrich), and sodium pyruvate (1 mM, Thermo Fisher Scientific). From day 56 onwards, dibutyryl-cAMP (db-cAMP, 0.5 mM, Sigma-Aldrich) and triiodothyronine (T3, 30 ng / mL, Sigma-Aldrich) were added to support neuronal maturation and terminal differentiation of Olig2-positive oligodendrocyte progenitor cells already present at this stage, respectively.

[0280] Phase 1 — Neural induction and spheroid formation (Davs 0-14)

[0281] OE-MSCs or olfactory basal stem cells were dissociated to single-cell suspension using Trypsin-EDTA(0.05%), washed with PBS, and seeded at a density of 50,000 cells / mL in neural induction medium in ultra-low attachment plates. For niche structuring, culture vessels were optionally pre-coated with Jaggedl-Fc (2 pg / mL) by incubation for 1 hour at room temperatureprior to cell seeding, to activate the Notch signaling pathway and modulate olfactory neuronal identity specification during the neural induction phase. Where indicated, Jaggedl-Fc coating was renewed at each medium change throughout the culture period.

[0282] From day 0 to day 4, cultures were maintained under static conditions at 37°C in 5% CO2 to allow initial spheroid formation. From day 4 to day 14, orbital agitation at 60 rpm was initiated to promote spheroid fusion and early organoid assembly. Medium was renewed by 50% every 2 to 3 days throughout Phase 1. Complete medium renewal was avoided at all stages to preserve autocrine and paracrine signaling factors.

[0283] At day 14, spheroids of approximately 200 to 500 pm in diameter were visually inspected for compactness and viability. Organoids exhibiting signs of necrosis or irregular morphology were excluded from further analysis.

[0284] Phase 2 — Organoid expansion and early differentiation (Days 14-42)

[0285] At day 14, neural induction medium was replaced by organoid differentiation medium. Cultures were maintained under continuous orbital agitation at 60 rpm. Medium was renewed by 50% every 2 to 3 days throughout Phase 2. Where Jaggedl-Fc coating had been applied during Phase 1, coating was renewed at each medium change.

[0286] Organoids were maintained under these conditions from day 14 to day 42, during which they increased progressively in diameter from approximately 200-500 pm to 500-1,000 pm. Olig2-positive oligodendrocyte progenitor cells were detected by immunofluorescence from day 42 onwards, confirming spontaneous engagement of the oligodendrocyte lineage under these differentiation conditions.

[0287] Phase 3 — Long-term maturation (Davs 42-90)

[0288] At day 42, organoid differentiation medium was replaced by maturation medium. Cultures were maintained under continuous orbital agitation at 60 rpm throughout Phase 3. Medium was renewed by 50% every 2 days. Complete medium renewal was not performed at any stage. From day 56 onwards, db-cAMP (0.5 mM) was added to the maturation medium to promote neuronal maturation and post-mitotic stabilization. Triiodothyronine (T3, 30 ng / mL) was additionally supplemented from day 56 to support terminal maturation of the Olig2 -positive oligodendrocyte progenitor population already present at this timepoint.Organoids were cultured under these conditions from day 42 to day 90. At day 90, organoids were collected for analysis as described below.

[0289] Immunohistochemistry (IHC)

[0290] Organoids were fixed in 4% paraformaldehyde overnight at 4°C, cryoprotected in 30% sucrose in lx PBS, embedded in Optimal Cutting Temperature (OCT) compound, frozen, and stored at -80 °C. Cryosections (20 pm) were collected and stored at -80 °C until use.

[0291] For immunostaining, sections were permeabilized and blocked in 0.2% Triton X-100, 4% horse serum, and 1% BSAin lx PBS for 1 h at room temperature. Sections were incubated overnight at 4 °C with primary antibodies against Ki67 (rabbit, Abeam abl6667, 1:250), Nestin (mouse, Thermofisher MAI-110, 1:100), DCX (mouse, Santa Cruz Biotechnology sc-271390, 1:250), NeuN (mouse, Merck MAB377, 1:100), GFAP (rabbit, Merck, Sigma SAB5700611, 1:500), Tujl (mouse, Biolegend 801201, 1:500), Sox2 (rabbit, Merck AB5603, 1:400), Pax6 (rabbit, Biolegend 901301, 1:250), MAP2 (chicken Arigo Biolaboratories ARG52328, 1:1000), OMP (mouse, Santa Cruz Biotechnology sc-365818, 1 :250), Peripherin (chicken, ThermoFisher PA1-10012, 1:2000), Olig2 (rabbit, Merck AB9610, 1:250).

[0292] The following day, sections were washed in lx PBS containing 0.1% Triton X-100 and incubated with the corresponding Alexa Fluor-conjugated secondary 488, 546, or 647 antibodies (Invitrogen, 1:500) for 1 h at room temperature.

[0293] Nuclei were counterstained with Hoechst 33258 (1:2000), and sections were mounted using Dako Fluorescence Mounting Medium. Sections were imaged using a Zeiss LSM 900 confocal microscope and processed with Fiji (ImageJ vl.54p).

[0294] Flow Cytometry (FACS)

[0295] Organoids were dissociated using Accutase (Thermo Fisher, Al 110501) for 3 minutes at 37 °C under 5% CO2 and 95% humidity conditions. Enzymatic activity was neutralized with serumcontaining medium then cell suspension was centrifuged at 300 x g for 5 minutes and resuspended in 1 x PBS. Cell viability was assessed using the Zombie Violet™ Fixable Viability Kit (BioLegend, 423113; 1:500) for 10 minutes at room temperature in the dark.

[0296] Surface staining was then performed using antibody cocktails in 1 x PBS for 20 minutes at 4 °C in the dark, including CD140a-PE-Texas Red (Miltenyi Biotec, 130-132-426; 1:50) and CD24-APC-Cy7 (Miltenyi Biotec, 130-112-659; 1:50).For intracellular staining, cells were washed with lx PBS and were processed using the Transcription Factor Staining Buffer Set (Miltenyi Biotec, 130-122-981) according to the manufacturer’s instructions, including fixation and permeabilization for 30 minutes at 4 °C, followed by washing with lx PBS.

[0297] Cells were then incubated with intracellular antibodies in 50ul permeabilization buffer for 20 minutes at 4 °C: AQP4-FITC (1:50, Miltenyi Biotec 130-137-720), GFAP-APC (1:50, Miltenyi Biotec 130-123-846), Nestin-PerCP-Cy5.5 (1:50, BD Biosciences 561231), Sox2-BV421 (1:50, Miltenyi Biotec 130-131-077) and Tujl-PE (1:50, Miltenyi Biotec 130-120-265). After staining, cells were washed in lx PBS, centrifuged at 300 x g for 5 minutes, and resuspended in 300 pL PBS. Compensation was performed using MACS All-in-One Comp Beads (Miltenyi Biotec, 130-138-867).

[0298] Flow cytometry was performed using a BD Symphony (BD Biosciences) and analyzed with Cytobank software. Gating was performed based on forward / side scatter to exclude debris, followed by singlet and viability gating. Cells were analyzed for CD 140a, CD24, AQP4, GFAP, Nestin, Sox2, and Tuj 1 expression using unstained controls for gating reference.

[0299] Nucleic Acid Extraction

[0300] Total RNA and genomic DNA were isolated from biopsies of human olfactory mucosa, eMSC organoid cultures (passage 2), basal cell organoid cultures (passage 2), all derived from three independent donors, and NSC-derived organoids (passage 2; Stem Cell Technologies, SCTi003-A), using TRI Reagent (Sigma-Aldrich) according to the manufacturer’s protocol.

[0301] For RNA extraction, after phase separation, the aqueous phase was transferred to a fresh tube and RNA was precipitated by adding 0.5 mL of 2-propanol per 1 mL of TRI Reagent. Samples were mixed and incubated for 10 minutes at room temperature, followed by centrifugation at 12,000 x g for 10 minutes at 4 °C to pellet RNA. The RNA pellet was washed with 75% ethanol and centrifuged at 7,500 x g for 5 minutes at 4°C. The RNA pellet was briefly air-dried and dissolved in RNase-free water at 55 °C for 15 minutes with gentle pipetting to facilitate dissolution. RNA quality was assessed spectrophotometrically, and samples were stored in ethanol at -20 °C for long-term storage.

[0302] For DNA extraction, the interphase and organic phase were subjected to ethanol precipitation by adding 0.3 mL of 100% ethanol per 1 mL of TRI Reagent, followed by incubation for 2-3 min at room temperature and centrifugation at 2,000 x g for 5 min at 4 °C. The DNA pellet was washed twice with 0.1 M trisodium citrate in 10% ethanol, followed by resuspension in 75%ethanol and incubation for 15 minutes. The pellets were then air-dried and resuspended in 8 mM NaOH. Insoluble material was removed by centrifugation at 12,000 * g for 10 minutes. DNA concentration was determined using a NanoDrop spectrophotometer by measuring absorbance at 260 nm and 280 nm (A260 / A280 ratio), and the resulting DNA-containing supernatant was collected for downstream analyses.

[0303] Telomere Length Quantification by qPCR

[0304] Telomere length was determined using the Human Telomere Length Absolute Quantification Kit TELH-AQ (RayBiotech, USA) following the manufacturer’s protocol. Briefly, qPCR reactions were prepared in a final volume of 20 pL containing 2X qPCR Master Mix, primer / probe mix, and 2 pL of genomic DNA (2 ng per reaction). Reference DNA and nuclease-free water were included as controls. All samples were run in triplicate.

[0305] Real-time PCR amplification was performed under cycling conditions according to the manufacturer’s instructions. Relative telomere length was calculated using the AACq method and normalized to the reference DNA.

[0306] RTqPCR Assay Analysis

[0307] RT-qPCR was performed to quantify the expression of senescence- and aging-associated genes, including CDKN2A (pl6), CDKN1 A (p21), LMNB1, and ELOVL2. RT-qPCR reactions were prepared according to the manufacturer’s instructions using the Reliance One-Step Multiplex RT-qPCR Supermix (Bio-Rad, #12010176) and PrimePCR™ TaqMan probe assays (Bio-Rad) specific for each target gene. Assays were multiplexed according to fluorophore compatibility and used at a final concentration of lx. RT-qPCR reactions were performed in technical triplicates using 1 pg of total RNA per reaction and were run on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) under cycling conditions according to the manufacturer’s recommendations for the one-step RT-qPCR system. No-template controls (NTCs) were included to monitor potential contamination. Fluorescence data were analyzed using CFX Manager or CFX Maestro software (Bio-Rad).

[0308] Relative gene expression was calculated using the AACt method and normalized to the geometric mean of the housekeeping genes RPL13A, GAPDH, and ACTB.

[0309] ResultseMSC-derived organoids exhibit proliferative and neural progenitor features at DIV56 Cerebral organoids derived from eMSCs isolated from patient cells were characterized by immunofluorescence at day 56 of culture. Cross-sections of eMSC-derived organoids were stained for markers of cell proliferation, neural stem cell identity, and early neuronal commitment.

[0310] Ki67, a marker of actively proliferating cells, was detected in a subset of cells within organoid cross-sections at day 56 (Figure 8A), demonstrating that a mitotically active progenitor population was maintained at this intermediate timepoint. The retention of proliferative capacity at day 56 indicates that organoids had not undergone premature terminal differentiation, and that an active progenitor reservoir capable of sustaining further cellular expansion was preserved under the applied culture conditions.

[0311] Nestin-positive cells were simultaneously identified throughout the organoid cross-sections (Figure 8B). Nestin is an intermediate filament protein expressed in neural stem and progenitor cells, and its detection at day 56 confirms the maintenance of an undifferentiated neural progenitor compartment within the organoid at this stage. The presence of Nestin-positive cells in organoids at day 56 suggests that eMSC-derived organoids establish and sustain a functional neural stem cell niche over extended culture periods.

[0312] Doublecortin (DCX)-positive immature neurons were additionally identified within organoid cross-sections at day 56 (Figure8C). DCX is a microtubule-associated protein expressed in newly bom and migrating neurons, and its detection confirms that early neuronal commitment and active neuroblast production were occurring within the organoids at this timepoint. The presence of DCX-positive neuroblasts alongside Ki67-positive proliferating progenitors and Nestin-positive neural stem cells indicates that neurogenesis was actively proceeding within the organoids at day 56, with newly committed neuronal precursors being continuously generated from the progenitor pool.

[0313] Collectively, the co-detection of Ki67, Nestin and DCX at day 56 demonstrates the establishment of a dynamic and heterogeneous cellular system within eMSC-derived organoids, characterized by the simultaneous maintenance of a proliferative progenitor compartment and ongoing neuronal commitment. These observations are consistent with a progressive neural differentiation process rather than a terminally differentiated static culture, and support the biological relevance of eMSC-derived organoids as dynamic models of neural tissue development and maturation.eMSC-derived organoids exhibit neuronal and glial differentiation at DIV56

[0314] The neuronal and glial composition of eMSC-derived organoids was further characterized at day 56 by multi-marker immunofluorescence analysis on cryosections.

[0315] NeuN-positive mature neurons and GFAP-positive astrocytes were simultaneously detected within organoid cross-sections at day 56 (Figure 9A-B). NeuN, a marker of post-mitotic mature neurons, confirmed that a proportion of cells had completed the neuronal differentiation program and acquired mature neuronal identity by this timepoint. The concurrent detection of GFAP-positive astrocytes demonstrates that glial differentiation proceeded in parallel with neuronal maturation, establishing a multicellular neural environment comprising both neuronal and astrocytic lineages within a single three-dimensional structure. The spatial organization of NeuN-positive and GFAP-positive cells within the organoid cross-sections further supports the establishment of a structured, tissue-like architecture reminiscent of the cellular organization observed in the central nervous system.

[0316] Co-immunostaining for Tujl and Sox2 revealed the spatial co-existence of differentiating neurons and Sox2 -positive neural progenitor cells within the same organoid cross-section at day 56 (Figure 7C). Tujl, a marker of early and mature neurons, was broadly distributed throughout the organoid, while Sox2-positive cells were identified in discrete zones, consistent with the maintenance of a localized neural progenitor compartment alongside regions of active neuronal differentiation. The persistence of Sox2 expression at day 56 indicates that eMSC-derived organoids had established a self-renewing neural progenitor niche capable of sustaining ongoing neurogenesis at this intermediate timepoint. The dynamic balance between Sox2-positive progenitor maintenance and Tujl -positive neuronal differentiation observed at day 56 is consistent with the cellular dynamics described in the developing human brain and supports the physiological relevance of the eMSC-derived organoid model.

[0317] Taken together, the immunofluorescence data at day 56 demonstrate that eMSC-derived organoids had established a heterogeneous multicellular neural environment comprising neural stem cells, immature neurons, mature neurons and astrocytes, and confirm the progressive and dynamic nature of neural differentiation within these organoids.

[0318] eMSC-derived organoids maintain a neural progenitor compartment at DIV90 Long-term culture of eMSC-derived organoids to day 90 was assessed to evaluate the persistence of neural progenitor populations and the degree of neuronal maturation achieved over extended culture.Immunofluorescence analysis at day 90 confirmed the sustained presence of Nestin-positive and Pax6-positive neural progenitor cells within organoid cross-sections (Figure 10A). The codetection of Nestin and Pax6 at this late timepoint indicates that the neural progenitor compartment was not exhausted during extended culture and that a neurogenic capacity was maintained up to day 90. Pax6 is a transcription factor characteristically expressed by radial glial progenitors and cortical neural progenitor cells in the developing central nervous system, and its detection at day 90 suggests that a subset of progenitors within eMSC-derived organoids had adopted a dorsal cortical progenitor-like identity over the prolonged culture period, further supporting the CNS identity of the organoids.

[0319] Co-immunostaining for Tujl and Sox2 at day 90 confirmed the continued co-existence of differentiating Tuj 1 -positive neurons and Sox2-positive neural progenitor cells at this advanced timepoint (Figure 10B), extending the observation made at day 56 to the long-term culture setting. The persistence of Sox2-positive progenitors alongside Tuj 1 -positive neurons at day 90 demonstrates that the neurogenic niche established within eMSC-derived organoids was maintained throughout the entire 90-day culture period, supporting the long-term self-renewal capacity of the neural progenitor compartment under the applied maturation conditions.

[0320] Progressive neuronal maturation and glial diversification in eMSC-derived organoids at DIV90

[0321] Assessment of neuronal maturation status at day 90 demonstrated progressive advancement of differentiation compared to earlier timepoints. Co-immunostaining for DCX and MAP2 within the same organoid cross-sections revealed the simultaneous presence of DCX-positive immature neurons and MAP2-positive mature neurons at day 90 (Figure 11 A). MAP2, a microtubule-associated protein expressed in mature neurons with established dendritic arborizations, confirmed that a proportion of neurons had reached an advanced stage of maturation by day 90. The co-existence of DCX-positive neuroblasts and MAP2-positive mature neurons within the same organoid section indicates that neuronal maturation proceeded in a progressive and asynchronous manner at day 90, with newly committed neurons continuing to be generated from the progenitor pool while earlier-bom neurons reached full maturity. This asynchronous pattern of neuronal maturation is reminiscent of the protracted neurogenic timeline described in the developing human cortex and further supports the biological relevance of the eMSC-derived organoid model.

[0322] Co-immunostaining for NeuN and GFAP at day 90 confirmed the simultaneous presence of NeuN-positive mature neurons and GFAP-positive astrocytes at this late timepoint (Figure 1 IB), extending the neuronal and glial co-differentiation observed at day 56 to the long-termculture setting. The detection of both mature neuronal and astrocytic populations at day 90 demonstrates the continued diversification of neural cell types over the extended culture period and supports the progressive establishment of a mature neural tissue-like environment within eMSC-derived organoids. The detection of both immature and mature neuronal markers alongside astrocytic markers at day 90 collectively indicates that eMSC-derived organoids had established a developing neural tissue-like structure characterized by progressive maturation and cellular diversification rather than a static terminally differentiated state.

[0323] eMSC-derived organoids do not express olfactory or peripheral neuronal markers at DIV90

[0324] A defining characteristic of the cerebral organoids of the present invention is the absence of olfactory sensory neuron identity. To assess whether eMSC-derived organoids retained olfactory tissue-specific identity after 90 days of culture, immunofluorescence analysis was performed for Olfactory Marker Protein (OMP) and Peripherin.

[0325] OMP, a marker of terminally differentiated olfactory sensory neurons, and Peripherin, an intermediate filament protein expressed in peripheral nervous system neurons including olfactory sensory neurons, were assessed on organoid cross-sections at day 90 (Figure 12). Immunofluorescence analysis revealed absent expression of both OMP and Peripherin within eMSC-derived organoids at this timepoint. The absence of OMP expression confirms that eMSC-derived organoids did not adopt the olfactory sensory neuron identity that would be expected if the cells had followed their tissue-of-origin differentiation program. Similarly, the absence of Peripherin confirms that the organoids did not acquire peripheral nervous system neuronal identity under the applied culture conditions.

[0326] The absence of these olfactory and peripheral neuronal markers at day 90, combined with the positive expression of central nervous system neuronal markers including NeuN, MAP2, DCX and Tuj 1 and glial markers including GFAP demonstrated at earlier timepoints, collectively establishes that eMSC-derived organoids have diverged from the olfactory tissue-specific phenotype of their cellular source and have acquired a central nervous system identity over the course of the 90-day culture period. This observation represents a key distinguishing feature of the cerebral organoids of the present invention compared to olfactory organoids previously described in the literature, which retain olfactory sensory neuron identity as evidenced by OMP expression.Olfactory basal cell-derived organoids exhibit proliferative and neural progenitor features at DIV56

[0327] Cerebral organoids generated independently from olfactory basal stem cells were characterized at day 56 to assess the neurogenic capacity of this distinct cell population and to establish whether findings obtained with eMSC-derived organoids were reproduced with a separate olfactory mucosa-derived cell source.

[0328] Immunofluorescence analysis of basal cell-derived organoid cross-sections at day 56 confirmed the presence of Ki67-positive proliferating cells (Figure 13A), demonstrating that a mitotically active progenitor compartment was maintained in basal cell-derived organoids at this timepoint, consistent with the pattern observed in eMSC-derived organoids. Pax6-positive neural progenitor cells were additionally identified within basal cell-derived organoid cross-sections at day 56 (Figure 13B), indicating that olfactory basal stem cells had adopted a neural progenitor-like identity under organoid-forming conditions. The detection of Pax6, a transcription factor associated with dorsal cortical neural progenitor identity in the central nervous system, in basal cell-derived organoids at day 56 suggests that these cells had undergone specification toward a CNS progenitor phenotype, supporting their capacity to generate central nervous system-like neural tissue.

[0329] Olfactory basal cell-derived organoids exhibit neuronal and glial differentiation at DIV56 Multi-marker immunofluorescence analysis at day 56 confirmed the simultaneous presence of neuronal and glial cell populations within basal cell-derived organoids.

[0330] Co-immunostaining for NeuN and GFAP revealed the co-detection of NeuN-positive mature neurons and GFAP-positive astrocytes within the same organoid cross-sections at day 56 (Figure 14A), demonstrating the capacity of olfactory basal stem cells to generate both neuronal and astrocytic lineages within a single three-dimensional organoid structure. The simultaneous neuronal and glial differentiation observed in basal cell-derived organoids at day 56 is equivalent to that observed in eMSC-derived organoids at the same timepoint, confirming that the two cell populations generate organoids of comparable cellular composition despite their distinct origins within the olfactory mucosa.

[0331] Co-immunostaining for Tuj 1 and Sox2 further revealed the spatial co-existence of Tuj 1 -positive differentiating neurons and Sox2-positive neural progenitor cells within basal cell-derived organoid cross-sections at day 56 (Figure 14B), consistent with the maintenance of a selfrenewing neural progenitor niche alongside active neuronal differentiation, as observed ineMSC-derived organoids. The simultaneous detection of DCX-positive immature neurons and MAP2-positive mature neurons within the same cross-section (Figure 14C) further confirmed the progressive and asynchronous nature of neuronal maturation in basal cell-derived organoids, with newly committed neuroblasts co-existing alongside neurons at more advanced stages of differentiation. Collectively, these findings demonstrate that basal cell-derived organoids establish a dynamic, multi-lineage neural cellular environment at day 56 that is comparable in complexity and composition to that of eMSC-derived organoids.

[0332] Olfactory basal cell-derived organoids do not express olfactory or peripheral neuronal markers at DIV56

[0333] Immunofluorescence analysis for OMP and Peripherin in basal cell-derived organoids at day 56 revealed absent expression of both olfactory and peripheral neuronal markers (Figure 15). This finding is particularly noteworthy given that olfactory basal stem cells are the direct in vivo progenitors of olfactory sensory neurons and might be expected to retain an olfactory differentiation bias under neural induction conditions. The complete absence of OMP and Peripherin expression in basal cell-derived organoids at day 56 demonstrates a clear and reproducible divergence from the olfactory sensory neuron differentiation program, confirming that basal cell-derived organoids had acquired a non-olfactory, central nervous system-like neuronal identity under the applied culture conditions. This finding is consistent with the absence of OMP and Peripherin observed in eMSC-derived organoids at day 90, demonstrating that the suppression of olfactory identity and the acquisition of CNS neuronal identity is a robust and reproducible property of the cerebral organoids of the present invention, irrespective of whether they are derived from olfactory ectomesenchymal stem cells or olfactory basal stem cells.

[0334] Olfactory basal cell-derived organoids exhibit glial lineage diversity at DIV56

[0335] The glial composition of basal cell-derived organoids was further characterized by immunofluorescence for GFAP and Olig2 at day 56. GFAP-positive astrocytes were detected throughout organoid cross-sections (Figure 16A), confirming robust and reproducible astrocytic differentiation in basal cell-derived organoids at this timepoint, consistent with findings at the neuronal level. Olig2-positive oligodendrocyte lineage cells were additionally identified within organoid cross-sections at day 56 (Figure 16B), demonstrating the spontaneous engagement of the oligodendrocyte progenitor lineage within basal cell-derived organoids under the applied culture conditions. The detection of Olig2 -positive cells without exogenous oligodendrocyte specification factors indicates that the culture conditions of the present invention are sufficient to support the spontaneous emergence of oligodendrocyteprogenitor cells from olfactory basal stem cells, further supporting the central nervous system glial identity of the resulting organoids. The simultaneous presence of GFAP-positive astrocytes and Olig2-positive oligodendrocyte progenitor cells confirms that basal cell-derived organoids generate two distinct central nervous system glial lineages, contributing to the cellular diversity of the organoids and reinforcing their classification as multi-lineage cerebral organoids with authentic CNS glial identity.

[0336] Quantitative analysis of neural cell populations at DIV18

[0337] Quantitative flow cytometry analysis was performed on dissociated organoids at day 18 of culture to assess the relative distribution of neural cell populations at an early differentiation timepoint in both basal cell-derived and eMSC-derived organoids (Figure 17). The experiment was performed in three independent biological replicates, each comprising three technical replicates, and results are expressed as mean percentage of marker-positive cells ± SEM.

[0338] In basal cell-derived organoids, quantitative analysis confirmed the presence of Nestin-positive and Sox2-positive neural progenitor populations, Tuj 1-positive neuronal populations, and GFAP-positive and AQP4-positive glial populations at day 18. The co-detection of progenitor and differentiated markers at this early timepoint demonstrates that basal cell-derived organoids had already initiated both progenitor compartment maintenance and active neuronal and glial differentiation by day 18. In eMSC-derived organoids, a comparable distribution of neural cell populations was observed, with similar proportions of progenitor, neuronal and glial markerpositive cells quantified across the same panel of markers. The quantitative agreement between basal cell-derived and eMSC-derived organoids at day 18 demonstrates that the two cell populations generate organoids of equivalent cellular composition at this early timepoint, confirming the reproducibility of the organoid generation method across distinct olfactory mucosa-derived stem cell populations and supporting the robustness of the platform for multidonor and multi-condition experimental applications.

[0339] Taken together, these results demonstrate that both olfactory basal stem cells and olfactory ectomesenchymal stem cells possess the intrinsic capacity to self-organize into three-dimensional cerebral organoids comprising diverse neural cell populations, including neural stem cells, immature and mature neurons, astrocytes and oligodendrocyte lineage cells. The absence of OMP and Peripherin expression in organoids derived from both cell populations, combined with the robust expression of central nervous system neuronal and glial markers, confirms that the cerebral organoids of the present invention have acquired a central nervous system identity that is distinct from the olfactory or peripheral nervous system identity of their tissue of origin, establishing their biological validity and supporting their application asphysiologically relevant models of the adult human brain for disease modeling, drug screening and personalized medicine.

[0340] Example 4: Generation of a vascular organoid from olfactory mucosa-derived cells

[0341] Materials

[0342] Olfactory ectomesenchymal stem cells (OE-MSCs) isolated from the lamina propria as described in Example 1 are used as the primary cellular source. OE-MSCs are expanded for a maximum of three to five passages prior to vascular differentiation to preserve their biological age characteristics.

[0343] Angiogenic differentiation medium consisted of Endothelial Cell Growth Medium-2 (EGM-2, Lonza) supplemented with recombinant human VEGF-A (50 ng / mL, PeproTech), recombinant human bFGF (20 ng / mL, PeproTech), recombinant human PDGF-BB (20 ng / mL, PeproTech), and recombinant human Angiopoietin-1 (100 ng / mL, PeproTech). Alternative angiogenic media formulations known to the skilled person may equally be used.

[0344] Methods — Common to both options

[0345] OE-MSCs are dissociated to single-cell suspension using Trypsin-EDTA (0.05%), washed with PBS, and seeded at a density of 50,000 cells / mL in ultra-low attachment 6-well plates (Coming) in angiogenic differentiation medium. Cultures are maintained at 37°C in 5% CO2 under orbital agitation at 60 rpm to promote three-dimensional spheroid self-organization. Medium is renewed by 50% every 2 days throughout the culture period. Complete medium renewal is avoided to preserve paracrine signaling factors.

[0346] Pericyte-like cell differentiation is assessed by immunofluorescence for NG2 (rabbit, Merck AB5320, 1:250) and PDGFR-P (rabbit, Abeam ab32570, 1:200) as described in Example 1. Mesenchymal stem cells, including OE-MSCs of neural crest origin, have been previously shown to adopt pericyte-like phenotypes under appropriate angiogenic culture conditions, consistent with their known pericyte-related properties (Crisan et al., 2008, Cell Stem Cell; Caplan, 2008, Journal of Cellular Biochemistry; Dellavalle et al., 2011, Nature Cell Biology).

[0347] Option 1: OE-MSC-derived pericyte-like cells combined with OE-MSC-derived endothelial-like cells

[0348] A second population of OE-MSCs from the same donor is subjected to endothelial transdifferentiation by culture on fibronectin-coated surfaces (10 pg / mL, Sigma-Aldrich) inendothelial induction medium comprising EGM-2 supplemented with recombinant human VEGF-A (50 ng / mL), recombinant human bFGF (20 ng / mL), recombinant human BMP4 (25 ng / mL, PeproTech), and recombinant human EGF (10 ng / mL, PeproTech) for 14 days.

[0349] Endothelial-like cells are characterized by immunofluorescence for CD31 (mouse, Dako M0823, 1:50) and VE-cadherin (rabbit, Abeam ab33168, 1:200). Following endothelial induction, OE-MSC-derived endothelial-like cells are dissociated and combined with OE-MSC-derived pericyte-like cells at a ratio of between 1 : 1 and 1 :4 (endothelial :pericyte) in ultralow attachment conditions under orbital agitation at 60 rpm in co-culture medium consisting of a 1:1 mixture of EGM-2 and angiogenic differentiation medium supplemented with VEGF-A (25 ng / mL) and Angiopoi etin- 1 (50 ng / mL).

[0350] This option generates a fully autologous vascular organoid derived exclusively from OE-MSCs of the same donor subject, without requiring any additional cellular source.

[0351] Option 2: OE-MSC-derived pericyte-like cells combined with endothelial cells co-isolated directly from the olfactory mucosa

[0352] Endothelial cells are co-isolated directly from the olfactory mucosa biopsy of the same donor subject, exploiting the fact that the olfactory mucosa constitutes a highly vascularized tissue naturally enriched in microvascular endothelial cells.

[0353] Endothelial cells are isolated from the olfactory mucosa biopsy by enzymatic digestion with Collagenase I (1 mg / mL, Sigma-Aldrich) for 30 minutes at 37°C, followed by mechanical dissociation, centrifugation at 300*g for 5 minutes, and positive selection of CD31-positive cells using anti-CD31 magnetic microbeads (Miltenyi Biotec) according to the manufacturer's instructions.

[0354] Isolated endothelial cells are expanded in EGM-2 on fibronectin-coated surfaces for a maximum of three passages prior to use. Endothelial cell identity is confirmed by immunofluorescence for CD31 and VE-cadherin as described above.

[0355] OE-MSC-derived pericyte-like cells and olfactory mucosa-derived endothelial cells are then combined at a ratio of between 1:1 and 1:4 (endothelial: pericyte) in ultra-low attachment conditions under orbital agitation at 60 rpm in co-culture medium as described in Option 1.

[0356] This option generates a vascular organoid in which both pericyte-like and endothelial cellular components originate from the same donor subject and from the same biopsy, preserving the biological age and molecular characteristics of the donor in both components.In both options, vascular spheroids are allowed to self-organize for 7 to 21 days under orbital agitation. Vascular organoids are collected at days 7, 14, and 21 for characterization by immunofluorescence for pericyte markers including NG2 and PDGFR-P, and endothelial markers including CD31 and VE-cadherin, and optionally for tight junction-associated proteins and BBB-related markers, using methods as described in Example 1 and as would be determined by the skilled person.

[0357] Example 5: Generation of vascularized cerebral organoids by sequential fusion, simultaneous assembly, matrix embedding, or microchannel perfusion

[0358] Materials

[0359] Cerebral organoids generated according to Examples 1 and 3, and vascular organoids generated according to Example 4, are used as starting materials for Options 1, 3 and 4.

[0360] Olfactory mucosa stem cells prepared as described in Example 1 are used as starting materials for Option 2.

[0361] In all options, all cellular components are derived from the same donor subject to enable fully autologous vascularized cerebral organoid assembly.

[0362] Co-culture fusion medium consists of a 1:1 mixture of maturation medium as described in Example 3 and angiogenic differentiation medium as described in Example 4, supplemented with recombinant human VEGF-A (25 ng / mL, PeproTech), recombinant human Angiopoietin-1 (50 ng / mL, PeproTech), recombinant human PDGF-BB (10 ng / mL, PeproTech), and recombinant human bFGF (10 ng / mL, PeproTech). Alternative co-culture medium formulations promoting simultaneous neural maturation and angiogenesis, as known to the skilled person, may equally be used.

[0363] Methods

[0364]

[0365] ial assembly by fusion :-formed cerebral and vascular

[0366]

[0367] Cerebral organoids generated according to Example 3 at any stage of neural differentiation between day 14 and day 90, and vascular organoids generated according to Example 4 at any stage of angiogenic differentiation between day 7 and day 21, are transferred together into ultralow attachment 6-well plates in co-culture fusion medium under orbital agitation at 60 rpm at 37°C in 5% CO2.Cerebral and vascular organoids are placed in close physical proximity at a ratio of 1:1 to 1:3 (cerebral: vascular) to promote spontaneous contact-mediated fusion and neurovascular assembly. Medium is renewed by 50% every 2 days.

[0368] Organoid fusion and progressive neurovascular integration are monitored by brightfield microscopy at days 1, 3, 7, 14, and 21 of co-culture. Fused vascularized cerebral organoids are maintained under orbital agitation for up to 30 days following initial fusion.

[0369] This option allows independent optimization of neural and vascular organoid maturation prior to assembly, enabling quality control of each component before fusion.

[0370] Option 2: Simultaneous co-assemblv of neural and vascular components

[0371] OE-MSCs destined for neural differentiation, OE-MSC-derived pericyte-like cells, and endothelial cells isolated from the olfactory mucosa of the same donor as described in Example 4 are combined at defined ratios in ultra-low attachment 6-well plates in a combination medium comprising neural induction medium as described in Example 3 supplemented with angiogenic factors as described in Example 4, under orbital agitation at 60 rpm at 37°C in 5% CO2.

[0372] The culture medium is progressively transitioned from neural induction medium to organoid differentiation medium and then to maturation medium as described in Example 3, with angiogenic factors maintained throughout at reduced concentrations to support vascular component development without compromising neural differentiation.

[0373] Medium is renewed by 50% every 2 to 3 days throughout the culture period of up to 90 days.

[0374] This option may promote more integrated neurovascular interactions from early stages of organoid development, enabling spontaneous co-organization of neural and vascular components within a single three-dimensional structure.

[0375] Option 3: Matrix embedding of cerebral organoid in a vascular matrix

[0376] Cerebral organoids generated according to Example 3 at day 42 of neural differentiation are embedded in a biocompatible three-dimensional matrix comprising extracellular matrix components including without limitation Matrigel, collagen I, fibrin, hyaluronic acid hydrogels, or PEG-based synthetic hydrogels, supplemented with OE-MSC-derived pericyte-like cells and / or olfactory mucosa-derived endothelial cells as described in Example 4, at a density of l*10A6 cells / mL.Embedded organoids are cultured in co-culture fusion medium at 37°C in 5% CO2 without agitation to allow vascular cell invasion and matrix remodeling around and within the cerebral organoid structure. Medium is renewed by 50% every 2 days. Matrix embedding is maintained for up to 21 days.

[0377] This option may promote directional vascular cell invasion into the cerebral organoid and formation of vascular network-like structures within the organoid matrix.

[0378]

[0379] 4: Microchannel of cerebral

[0380]

[0381] with vascular cells

[0382] Cerebral organoids generated according to Example 3 are transferred to microfluidic devices comprising microchannels of defined dimensions in biocompatible materials such as poly dimethylsiloxane (PDMS) or thermoplastic polymers.

[0383] Microchannels are coated with fibronectin (10 pg / mL) and seeded with endothelial cells derived from OE-MSCs by transdifferentiation and / or isolated from the olfactory mucosa of the same donor as described in Example 4, to generate endothelialized microchannels.

[0384] Cerebral organoids are placed in adjacent culture chambers connected to the endothelialized microchannels and perfused with co-culture fusion medium under defined flow conditions using a peristaltic pump or pressure-driven flow system, to promote neurovascular interactions between the endothelial lining of the microchannels and the cerebral organoid, using configurations and methods as would be determined by the skilled person.

[0385] In all options, vascularized cerebral organoids are collected at defined timepoints for characterization by immunofluorescence for neuronal markers including TUJ1, NeuN and MAP2, glial markers including GFAP and Olig2, and vascular markers including NG2, PDGFR-P, CD31 and VE-cadherin, as described in Examples 1, 3 and 4, to confirm the coexistence of neural and vascular cell populations within a single three-dimensional organoid structure.

[0386] Absence of OMP and Peripherin expression in the neural component is confirmed by immunofluorescence as described in Example 3, confirming maintenance of CNS identity of the neural component within the vascularized cerebral organoid.

[0387] Additional characterization for tight junction-associated proteins, BBB-related markers, and functional barrier properties may be performed using methods as would be determined by the skilled person.Conclusions

[0388] Together, these results demonstrate that olfactory mucosa-derived stem cells — whether basal cells from rodents or ectomesenchymal stem cells from human donors — possess the ability to self-organize into structured organoids and give rise to diverse neural lineages. The spatial organization, marker expression, and cross-condition reproducibility confirm the biological relevance and technical feasibility of this platform for translational neuroscience applications.

Claims

57CLAIMS1. A method of producing a cerebral organoid exhibiting central nervous system identity, comprising culturing and differentiating olfactory mucosa stem cells of the olfactory mucosa of a subject into neurons and glial cells, said method being deprived of a reprogramming step.

2. The method of claim 1, wherein the cultivation step leads to formation of cellular spheres and the differentiation step is performed before or after aggregation of the cellular sphere into organoids.

3. The method of claim 1 or 2, comprising the steps of (i) culturing the olfactory mucosa stem cells to obtain cellular spheres; (ii) aggregating said cellular spheres to form organoids; (iii) culturing successively said organoids in adapted culture medium to differentiate cells of the organoids respectively into neurons and glial cells, in particular astrocytes and oligodendrocytes, in order to obtain cerebral organoids.

4. The method of claim 1 or 2, comprising the steps of (i) culturing the olfactory mucosa stem cells to obtain cellular spheres; (ii) culturing said spheres in adapted culture medium to differentiate the cells respectively into neurons and glial cells, in order to obtain spheres of neurons and spheres of glial cells, in particular spheres of astrocytes and spheres of oligodendrocytes; (iii) aggregating spheres of neurons and spheres of glial cells to form cerebral organoids.

5. The method of claim 1 or 2, comprising the steps of (i) transdifferentiating the olfactory mucosa stem cells to obtain neuronal stem cells; (ii) culturing the neuronal stem cells to obtain neurospheres; (iii) aggregating said neurospheres to form neuronal organoids; (iv) culturing said neuronal organoids to differentiate the neuronal stem cells into neurons and glial cells, in particular astrocytes and oligodendrocytes.

6. The method of any one of claims 1 to 5, wherein the olfactory mucosa stem cells are selected from olfactory basal stem cells, olfactory ectomesenchymal stem cells (OE-MSCs) or a combination thereof.

7. The method of any one of claims 1 to 6, wherein the olfactory mucosa stem cells have been previously obtained from a non-human mammal or a human.

588. The method of any one of claims 1 to 7, wherein the olfactory stem cells are obtained from a subject exhibiting a neurological disorder, preferably selected from a neurodegenerative disorder or a neuropsychiatric disorder, more preferably selected from Alzheimer's disease, Parkinson's disease, schizophrenia, or bipolar disorder.

9. The method of any one of claims 1 to 8, wherein the organoid comprises neurons expressing TUJ1 (class III P-tubulin) and / or the neuronal nuclear protein (NeuN).

10. The method of any one of claims 1 to 9, wherein the organoid comprises glial cells selected from astrocytes, preferably expressing Glial Fibrillary Acidic Protein (GFAP), oligodendrocytes, preferably expressing Olig2, and / or ependymal cells, and any combination thereof.

11. The method of any one of claims 1 to 10, wherein the cerebral organoid is substantially deprived of neurons expressing Olfactory Marker Proteins (OMP) and / or neurons expressing Peripherin.

12. The method of any one of claims 1 to 11, further comprising vascularizing the cerebral organoid.

13. The method of claim 12, wherein the vascularization step comprises (i) producing a vascular organoid from olfactory mucosa-derived cells of a subject, (ii) assembling said cerebral organoid and said vascular organoid in order to promote neurovascular interactions leading to a vascularized cerebral organoid.

14. The method of claim 13, wherein the step of producing the vascular organoid (i) comprises differentiating olfactory ectomesenchymal stem cells (OE-MSCs) under angiogenic conditions to obtain pericyte-like cells expressing one or more markers selected fromNG2, PDGFR-P and a-SMA, optionally in combination with endothelial cells derived from OE-MSCs by transdifferentiation and / or isolated directly from the olfactory mucosa of the subject, and assembling said cells into a three-dimensional vascular organoid structure, said method being preferably deprived of a reprogramming step.

15. The method of claim 13 or 14, wherein the assembling step (ii) is performed by sequential fusion at any stage of organoid development, or by simultaneously assembly, or by embedding the cerebral organoid within a vascular matrix comprising extracellular matrix components and vascular cells derived from OE-MSCs and / or isolated from the olfactory mucosa of a subject, or by perfusion of the cerebral organoid through microchannels comprising vascular cells.5916. The method of claim 15, wherein the sequential fusion comprises co-culturing a pre-formed cerebral organoid and a pre-formed vascular organoid at any stage of their respective development in physical proximity under conditions promoting spontaneous organoid fusion and neurovascular assembly.

17. The method of claim 15, wherein the simultaneous assembly comprises co-culturing OE-MSCs destined for neural differentiation and cells destined for vascular differentiation from the outset in a single culture vessel under conditions allowing spontaneous co-organization of both neural and vascular components into a vascularized cerebral organoid.

18. The method of claim 15, wherein the vascular matrix for embedding the organoids comprises hydrogel-based matrices, bioprinted scaffolds, or any biocompatible three-dimensional matrix supporting vascular cell growth and neurovascular interactions.

19. The method of claim 15, wherein the assembly comprises perfusion of the cerebral organoid through microchannels lined with endothelial cells derived from OE-MSCs by transdifferentiating and / or isolated from the olfactory mucosa of a subject, under defined flow conditions promoting vascular lumen formation and neurovascular interactions.

20. The method of any one of claims 15 to 19, wherein the cerebral organoid and the vascular organoid are both derived from cells of the same subject.

21. A cerebral organoid obtainable by the method of any one of claims 1 to 20, comprising neurons expressing TUJ1 (class III P-tubulin), the neuronal nuclear protein (NeuN) and / or the Microtubule Associated Protein-2 (MAP2) and glial cells selected from astrocytes and / or oligodendrocytes.

22. A cerebral organoid, comprising neurons expressing TUJ1 (class III P-tubulin), and / or the neuronal nuclear protein (NeuN) and / or the Microtubule Associated Protein-2 (MAP2) and glial cells selected from astrocytes and / or oligodendrocytes, wherein the cellular aging and key epigenetic modifications of the olfactory mucosa stem cells used to produce the organoid are maintained in the organoid.

23. The cerebral organoid according to claim 21 or 22, wherein the cerebral organoid is deprived of neurons expressing Olfactory Marker Proteins (OMP) and / or neurons expressing Peripherin.

24. The cerebral organoid according to any one of claims 21 to 23, comprising astrocytes expressing GFAP and / or oligodendrocytes expressing Olig2.6025. The cerebral organoid according to any one of claims 21 to 24, further comprising neural stem cells.

26. The cerebral organoid according to any one of claims 21 to 25, comprising neurons expressing TUJ1, NeuN and MAP2, astrocytes expressing GFAP and oligodendrocytes expressing Olig2, and neural stem cells, said cerebral organoid being further deprived of neurons expressing Olfactory Marker Proteins (OMP) and neurons expressing Peripherin.

27. The cerebral organoid according to any one of claims 21 to 26, wherein the olfactory mucosa stem cells have been previously obtained from a non-human mammal or a human.

28. The cerebral organoid according to any one of claims 21 to 27, wherein the olfactory mucosa stem cells have been previously obtained from a subject exhibiting a neurological disorder, preferably selected from a neurodegenerative disorder or a neuropsychiatric disorder, more preferably selected from Alzheimer's disease, Parkinson's disease, schizophrenia, or bipolar disorder, or from a healthy subject.

29. The cerebral organoid according to any one of claims 21 to 28, wherein the cerebral organoid is further vascularized.

30. The vascularized cerebral organoid of claim 29, wherein both the neural and vascular components are derived from cells of a same subject, thereby preserving the biological age and molecular characteristics of the donor in both components.

31. The vascularized cerebral organoid of claim 29 or 30, derived from cells of a subject exhibiting a neurological disorder, wherein the organoid retains the pathological molecular signature of said subject in both the neural and vascular components.32 The vascularized cerebral organoid according to any one of claims 29 to 31, comprising a neural component comprising neurons and glial cells, said neural component being substantially devoid of neurons expressing OMP and Peripherin, and a vascular component comprising pericyte-like cells derived from OE-MSCs expressing one or more markers selected from NG2, PDGFR-P and a-SMA, and / or endothelial cells derived from OE-MSCs by transdifferentiating and / or isolated from the olfactory mucosa of a subject, optionally further comprising tight junction proteins and / or BBB-associated markers.

33. A method of producing a vascular organoid from olfactory mucosa-derived cells of a subject, comprising differentiating olfactory ectomesenchymal stem cells (OE-MSCs) under angiogenic conditions to obtain pericyte-like cells expressing one or more markers selected61from NG2, PDGFR-P and a-SMA, optionally in combination with endothelial cells derived from OE-MSCs by transdifferentiating and / or isolated directly from the olfactory mucosa of a subject, and assembling said cells into a three-dimensional vascular organoid structure, said method being deprived of a reprogramming step.

34. A vascular organoid derived from olfactory mucosa-derived cells of a subject, comprising pericyte-like cells derived from OE-MSCs expressing one or more markers selected fromNG2, PDGFR-P and a-SMA, optionally in combination with endothelial cells derived from OE-MSCs by transdifferentiation and / or isolated directly from the olfactory mucosa of a subject, wherein the cellular aging and key epigenetic modifications of the olfactory mucosa stem cells used to produce the organoid are maintained in the organoid.

35. Use of olfactory mucosa stem cells from olfactory mucosa of a subject to produce a cerebral organoid exhibiting central nervous system identity.

36. The use of claim35, wherein the olfactory mucosa stem cells are selected from olfactory basal stem cells, olfactory ectomesenchymal stem cells and combination thereof.

37. The use of claim 35 or 36, wherein the olfactory mucosa stem cells are from a subject exhibiting a neurological disorder, preferably selected from a neurodegenerative disorder or a neuropsychiatric disorder, more preferably selected from Alzheimer's disease, Parkinson's disease, schizophrenia, or bipolar disorder.

38. Use of the cerebral organoid of any one of claims 21 to 32 for screening for a prophylactic or therapeutic drug for a neurological disorder.

39. Use of the cerebral organoid of any one of claims 21 to 32 for modeling brain aging processes or age-related neurological conditions in vitro.

40. Use of the cerebral organoid of any one of claims 21 to 32 for assessing neurotoxicity of a compound.

41. Use of the cerebral organoid of any one of claims 21 to 32 for personalized medicine, comprising generating a cerebral organoid from olfactory mucosa stem cells of a specific patient and assessing the response of said organoid to one or more therapeutic agents.

42. The use according to any one of claims 35 to 41, wherein the cerebral organoid is generated from olfactory mucosa stem cells previously obtained from a subject exhibiting a neurological disorder, preferably selected from a neurodegenerative disorder or a neuropsychiatric disorder,more preferably selected from Alzheimer's disease, Parkinson's disease, schizophrenia, or bipolar disorder, and wherein the organoid retains the pathological molecular signature of said subject.

43. Use of the vascular organoid of claim 34 or the vascularized cerebral organoid of any one of claims 29 to 32, for screening for a prophylactic or therapeutic drug for a neurological disorder.

44. Use of the vascular organoid of claim 34 or the vascularized cerebral organoid of any one of claims 29 to 32, for modeling blood-brain barrier function or neurovascular interactions in vitro.

45. Use of the vascular organoid of claim 34 or the vascularized cerebral organoid of any one of claims 29 to 32, for assessing vascular toxicity or neurotoxicity of a compound.

46. Use of the vascularized cerebral organoid of any one of claims 29 to 32 for modeling cerebrovascular disorders, neuroinflammation, or brain ischemia in vitro.

47. Use of the vascularized cerebral organoid of any one of claims 29 to 32 for modeling brain aging processes including age-related vascular changes in vitro.